Alzheimer’s Disease

Orthomolecular Interventions

Orthomolecular interventions are nutrients and actions that promote health by supporting the body’s specific biochemical needs.

Beneficial dietary approaches

Dietary approaches influence many of the biological processes involved in Alzheimer’s disease and cognitive decline. They have actions that support brain health and can help reduce the risk and progression of cognitive decline.

Actions of the Mediterranean diet in preventing and addressing Alzheimer’s disease include:

  • improving cardiovascular health – which reduces the risk of Alzheimer’s disease and related dementias (Ellouze et al., 2023)
  • improving cerebral blood flow – which enhances oxygen and nutrient delivery to the brain and supports healthy cognitive aging (Ellouze et al., 2023)
  • improving mitochondrial function – which supports neuronal energy production and healthy brain aging (Ellouze et al., 2023)
  • reducing oxidative stress and neuroinflammation (Ellouze et al., 2023; Chu et al., 2022)
  • supporting neurogenesis and neuronal survival (Chu et al., 2022)
  • providing neuroprotective nutrients – which support multiple pathways involved in brain health (Chu et al., 2022) including:
    • B vitamins
    • antioxidants
    • polyphenols (plant compounds)
    • omega-3 fatty acids

Actions of intermittent fasting in preventing and addressing Alzheimer’s disease include:

  • promoting the transition to ketone metabolism – which provides an alternative energy source for neurons when cerebral glucose availability is reduced (Elias et al., 2023)
  • suppressing inflammatory signalling pathways and lowering pro-inflammatory cytokine production (Chu et al., 2022)
  • reducing oxidative stress (Elias et al., 2023)
  • activating cellular stress-response pathways – which enhances antioxidant defenses, DNA repair, and cellular resilience (Elias et al., 2023)
  • suppressing mTOR signalling – which enhances cellular resilience and improves mitochondrial function and ATP production (Chu et al., 2022)
  • improving mitochondrial function – which increases ATP production and supports neuronal energy metabolism (Chu et al., 2022)
  • increasing autophagy – which removes damaged proteins and cellular components that contribute to Alzheimer’s pathology (Chu et al., 2022)
  • reducing amyloid accumulation – through β-hydroxybutyrate-mediated effects on gene regulation and amyloid-related cellular pathways (Chu et al., 2022)
  • enhancing synaptic plasticity and hippocampal neurogenesis (Chu et al., 2022)
  • modulating the gut microbiome – which improves neurotransmitter balance in the brain (Chu et al., 2022)

Actions of a ketogenic diet in preventing and addressing Alzheimer’s disease include:

  • providing ketone bodies as an alternative brain fuel – which improves neuronal energy production when cerebral glucose metabolism is impaired (Castro et al., 2023)
  • reducing neuroinflammation – which helps limit inflammation-induced blood–brain barrier breakdown by (Chu et al., 2022; Norwitz et al., 2021):
    • activating PPAR-γ (a receptor that regulates genes involved in metabolism, inflammation, and cellular function)
    • suppressing NF-κB signalling
    • reducing the production of pro-inflammatory cytokines
  • improving mitochondrial function – which increases ATP production and activates antioxidant pathways that reduce oxidative stress (Chu et al., 2022)
  • supporting synaptic maintenance – which helps preserve communication between neurons and supports cognitive function (Lilamand et al., 2021)
  • decreasing amyloid deposition, enhancing amyloid clearance, reducing amyloid toxicity, and limiting tau-related pathology (Chu et al., 2022; Lilamand et al., 2021)
  • supporting neuronal growth and repair – through ketone-mediated changes in gene expression that increase BDNF production and support learning and memory (Norwitz et al., 2021; Chu et al., 2022)

Vitamin B1 (Thiamine)

Actions of vitamin B1 in preventing and addressing Alzheimer’s disease include:

  • supporting activity of thiamine-dependent enzymes involved in glucose metabolism – which helps maintain ATP production and mitochondrial function, reducing neuronal energy deficits (Fessel, 2021; Peres et al., 2022; Gibson et al., 2016)
  • supporting acetyl-CoA (a key metabolic molecule) production – which supports ATP production and may support acetylcholine neurotransmission (Fessel, 2021; Gibson et al., 2016)

Benfotiamine
Benfotiamine is a fat-soluble derivative of vitamin B1 (thiamine) that is absorbed more efficiently than thiamine and produces higher, longer-lasting thiamine levels in the body.

Actions of benfotiamine reported in human clinical studies and supported by animal studies include (Gibson et al., 2020; Pan et al., 2010):

  • reducing cognitive decline in people with mild Alzheimer’s disease (Gibson et al., 2020)
  • reducing amyloid-β plaque formation and tau phosphorylation – by suppressing glycogen synthase kinase-3 (GSK-3) activity (Pan et al., 2010)

Causes of vitamin B1 (thiamine) deficiencies:

  • low dietary thiamine intake
  • high intake of polished white rice or refined grains
  • poor nutrient absorption
  • excessive alcohol consumption
  • malabsorption syndromes – Crohn’s, celiac disease, chronic diarrhea
  • eating disorders
  • excessive coffee or tea (thiaminease – an Overview | ScienceDirect Topics, n.d.)
  • high intake of sulfites in food and drinks (Sulfites – USA | Food Allergy Research & Resource Program | Nebraska, n.d.)
  • certain medications

Top food sources of vitamin B1 based on typical serving size:

  • pork, lean
  • green peas
  • long-grain, brown rice
  • pecans
  • lentils

Comprehensive food list:
Table 2. Some Food Sources of Thiamin (Thiamin, 2014)
https://lpi.oregonstate.edu/mic/vitamins/thiamin

Referenced Dietary Intakes
RDAs for Thiamine (mg/day)
Children (9-13 years): 0.9 (M) 0.9 (F)
Adolescents (14-18 years): 1.2 (M) 1.0 (F)
Adults (19 years and older): 1.2 (M) 1.1 (F)

Vitamin B1 Supplementation

Amounts of thiamine used in practice and research range from 50–1000 mg/day in divided doses. (Thiamin, 2014)

SAFETY, SIDE EFFECTS
There are no well-established toxic effects from consumption of excess thiamine in food or through long-term, oral supplementation (up to 200 mg/day) (Thiamin, 2014).

VITAMIN B1 AND MEDICATIONS
Thiamine is not known to interact with any medications (Thiamin, n.d.).

Thiamine and magnesium
Magnesium is required for thiamine to function, so ensuring adequate magnesium while supplementing is important.

  • The enzyme that converts thiamine to its active form (TPP) requires magnesium.
  • All known enzymes that require TPP also require magnesium to function (Fattal-Valevski, 2011).

Base amounts for addressing thiamine deficiency (von Merveldt-Guevara, 2024):

  • thiamine – 50–100 mg
  • magnesium – 360–700 mg

These nutrients should be taken in divided doses.

Vitamin B3 (Niacin)

The active biologically active forms of vitamin B3, together with related NAD⁺ precursors, help maintain cellular levels of nicotinamide adenine dinucleotide (NAD⁺). NAD⁺ is an essential coenzyme involved in cellular energy production, DNA repair, antioxidant defence, and other processes that help maintain brain health.

The different forms of vitamin B3 and related NAD⁺ precursors do not all act through the same mechanisms:

  • Nicotinic acid (niacin) → increases NAD⁺ and activates HCAR2
  • Nicotinamide → increases NAD⁺ but has little or no HCAR2 activation
  • Nicotinamide riboside (NR) and NMN → primarily increase NAD⁺ without HCAR2 activation

Increasing intracellular NAD⁺ supports processes involved in neuronal health, including:

  • supporting mitochondrial health and energy production (Linus Pauling Institute, 2018)
  • supporting cellular energy metabolism (Linus Pauling Institute, 2018)
  • acting as a mitochondrial antioxidant (Morris et al., 2004)
  • supporting DNA repair (Linus Pauling Institute, 2018; Morris et al., 2004)
  • supporting calcium homeostasis (Linus Pauling Institute, 2018; Morris et al., 2004)
  • supporting myelination and dendritic growth (Morris et al., 2004)

Activating HCAR2
HCAR2 is a receptor expressed on immune cells, including brain microglia. Activation by niacin (nicotinic acid) helps regulate neuroinflammation, promotes amyloid-β clearance, and may help reduce neuronal loss (Moutinho et al., 2020).

Causes of vitamin B3 deficiencies

  • inadequate oral intake
  • poor bioavailability from grain sources
  • issues with absorption of tryptophan
  • some metabolic disorders
  • long-term chemotherapy treatments

Top food sources of vitamin B3 based on serving size:

  • chicken
  • tuna
  • turkey
  • salmon
  • beef

Comprehensive food list:
Table 2. Some Food Sources of Niacin (Niacin, 2014)

Tolerable Upper Intake Level (UL) for Niacin and niacinamide (mg/day)
Children (9-13 years): 20 mg/day
Adolescents (14-18 years): 30 mg/day
Adults (19 years and older): 35 mg/day

The Food and Nutrition Board set the tolerable upper intake level (UL) for niacin (nicotinic acid and nicotinamide) at 35 mg/day in adults to avoid the adverse effect of flushing. (Niacin, 2014)

Vitamin B3 Supplementation

1. Vitamin B3 (niacin) Supplementation

  • Amounts of niacin/nicotinic acid used in practice and research range from 100–3000 mg/day in divided doses (Niacin, 2014).

The niacin flush
Niacin causes capillaries to dilate which results in increased blood flow to the skin. This effect is known as the “niacin flush”. It is harmless, but can be uncomfortable.

About the niacin flush:

  • Causes a“prickly heat” sensation
  • Causes the skin to feel warm and become red
  • The flush begins in the forehead and works its way down the body, rarely affecting the toes
  • The flush usually begins a few minutes after taking the niacin supplement
  • The flush may last for several hours
  • Each time that niacin is taken, the degree of flushing decreases
  • Most people will flush with 100 mg of niacin, some people will flush with less than 100 mg
  • The higher the initial niacin dose, the greater the initial flush
  • If the niacin supplementation is interrupted for several days, the flushing will resume as if starting for the first time, but not as strong as the original flush

Reducing the niacin flush
In a guide for patients, updated in 2018 by his long-time assistant Frances Fuller, Dr. Hoffer explained ways to mitigate the niacin flush.

Actions to take include:

  • Taking 2 to 4 g of vitamin C at the beginning of a meal, and then taking niacin at the end of the meal (Vitamin C decreases the flush by neutralizing histamine in the blood).
  • Taking the niacin with a cold beverage
  • Avoiding hot showers or baths immediately after taking niacin
  • Starting with a lower amount of niacin and gradually increasing the daily dose—for example starting with 125 mg, then doubling the amount every 4-5 days (flushing should stop shortly after reaching 1,000 mg per day

Chronic exposure to allergens, either food-based or environmental, can stimulate continuous production of histamine. This ongoing supply of histamine can be a reason why some people continue to flush, even after long-term niacin supplementation.

SAFETY, SIDE EFFECTS

  • People who may be more susceptible to effects of excess niacin intake include those with abnormal liver function or liver disease, diabetes, active peptic ulcer disease, gout, cardiac arrhythmias, inflammatory bowel disease, migraine headaches, or alcoholism (Niacin, 2014).
  • Extended-release niacin has been associated with increased risk of serious adverse events (Anderson et al. 2014).
  • Although rare, serum aminotransferase levels should periodically be tested to monitor possible hepatotoxicity in patients who take large doses of vitamin B3 (Gaby, 2011).

2. Vitamin B3 (nicotinamide) Supplementation

  • Amounts of nicotinamide used in practice and research range from 300–3000 mg/day in divided doses (Niacin, 2014).
  • Dr. Abram Hoffer recommended 1500–6000 mg of niacinamide for all patients with psychiatric syndromes (Hoffer et al., 1995).
  • Most people need minimum 2000–4500 mg/day of niacinamide, and relief of symptoms can be seen within one month (Prousky, 2015).

SAFETY, SIDE EFFECTS

  • Niacinamide supplementation doses of 1500-6000 mg have been used for extended amounts of time in children and adolescents without side effects or complications (Hoffer, 1971: Hoffer 1999).
  • Niacinamide does not generally cause flushing. The most common side effects of niacinamide supplementation are sedation (Werbach & Leibsohn, 1997, p133-60).
  • At very high doses (≥10 g/day), nausea, vomiting, and signs of liver toxicity (elevated liver enzymes, jaundice) have been observed (Niacin, 2014).

Vitamin B6, folate, and vitamin B12

Vitamin B6, folate, and vitamin B12 work together to keep homocysteine levels in balance through different but complementary processes.

Combined actions of vitamin B6, folate, and vitamin B12 in preventing and addressing Alzheimer’s disease include:

  • supporting methionine cycle (a biochemical pathway that recycles methionine) function – by enabling the reactions that recycle homocysteine and regenerate methionine, which supports methylation-dependent brain function (Gregory et al., 2016; Smith et al., 2018; Zhang et al., 2021; El-Mezayen et al., 2022)
  • supporting homocysteine metabolism – by converting it to methionine (folate, vitamin B12) or into cysteine (vitamin B6), which helps reduce homocysteine-associated vascular and neuronal damage (Gregory et al., 2016; Smith et al., 2018; Zhang et al., 2021; El-Mezayen et al., 2022)
  • supporting methylation reactions – which help maintain normal DNA methylation, gene regulation, neuronal function, and brain health (Zhang et al., 2021; El-Mezayen et al., 2022)

Other actions of vitamin B6 in preventing and addressing Alzheimer’s disease include:

  • Serving as a cofactor (a helper molecule that helps enzymes work) in the synthesis and metabolism of neurotransmitters – including serotonin, dopamine, norepinephrine, GABA, glutamate, glycine, D-serine, and histamine (Kennedy, 2016).
  • maintaining excitatory–inhibitory neurotransmission (balancing stimulating and calming signals) – by enabling the conversion of glutamate into GABA (Kennedy, 2016)
  • Supporting glutathione synthesis by helping convert homocysteine into cysteine, a key building block of glutathione (Gregory et al., 2016)

Causes of B6 deficiencies

  • inadequate dietary intake
  • medications, including anti-tuberculosis drugs, antiparkinsonians, nonsteroidal anti-inflammatory drugs, and oral contraceptives, may interfere with vitamin B6 metabolism. (Vitamin B6, 2014)
  • alcoholism – due to low intake and impaired metabolism of vitamin B6

Deficiency of vitamin B6 can be identified by:

  • the absence of dreams, or the inability to remember dreams
  • having disturbing dreams or nightmares

Top sources of vitamin B6 based on serving size:

  • salmon
  • potato
  • turkey
  • avocado

Comprehensive food list:

Table 2. Some Food Sources of vitamin B6 (Vitamin B6, 2014)

https://lpi.oregonstate.edu/mic/vitamins/vitamin-B6

Referenced Dietary Intakes
RDAs for vitamin B6 (mg/day)
Adolescents (14-18 years): 1.3 (M) 1.2 (F)
Adults (19-50 years): 1.3 (M) 1.3 (F)
Adults (51 years and older): 1.7 (M) 1.5 (F)

Tolerable Upper Intake: 100 mg/day
(Office of Dietary Supplements – Vitamin B6, n.d.)

Vitamin B6 Supplementation

  • Amounts of vitamin B6 used in practice and research range from 20–6000 mg/day in divided doses (Office of Dietary Supplements – Vitamin B6, n.d.).

SAFETY, SIDE EFFECTS

  • Doses above 100 mg/day may, in some people, cause side effects that include nausea, vomiting, stomach pain diarrhea, headache, tingling, and sleepiness. The risk of negative effects can be reduced by supplementing  magnesium 6.6–8.8 mg /kg as well as a B-complex vitamin (Prousky, 2015).
  • Monitoring for symptoms of sensory neuropathy should be considered with long-term supplementation of more than 200 mg/day of vitamin B6 (Gaby, 2011).

VITAMIN B6 AND MEDICATIONS

  • High doses of vitamin B6 have been found to decrease the efficacy of phenobarbital, phenytoin, and L-Dopa (Vitamin B6, 2014).

Other actions of folate in preventing and addressing Alzheimer’s disease include:

  • supporting DNA methylation – which influences Alzheimer’s disease-related gene regulation (Zhang et al., 2021)
  • reducing oxidative stress – which protects neurons from oxidative injury (Zhang et al., 2021)
  • Reducing amyloid-β production and the buildup of amyloid plaques in the brain – by regulating the activity of the enzymes β-secretase and γ-secretase (Fuso et al., 2007; Zhang et al., 2021).
  • inhibiting tau phosphorylation – by modulating kinase and phosphatase activity (Sontag and Sontag, 2014; Zhang et al., 2021)

Causes of folate deficiencies:

  • low dietary intake
  • poor absorption
  • gastrointestinal issues
  • chronic alcoholism
  • smoking
  • oral contraceptives (Gaby, 2011)
  • drug interactions (Folate, 2014)
  • genetic variations in folate metabolism, for example variations the MTHFR gene  (“Folate”, 2014)

Top food sources of folate by serving size:

  • lentils
  • chickpeas
  • asparagus
  • spinach
  • lima beans

Comprehensive food list:
Table 2. Some Food Sources of folate and folic acid (Folate, 2014)
https://lpi.oregonstate.edu/mic/vitamins/folate

Dietary reference values
RDAs for folate (mcg/day)
Adolescents (14-18 years): 400 (M) 400 (F)
Adults (19-50 years): 400 (M) 400 (F)
Adults (51 years and older): 400 (M) 400 (F)

Tolerable Upper Intake
Not establish due to low potential for toxicity.

The Food and Nutrition Board of the US Institute of Medicine recommends a maximum intake of 1000 mcg of the folic acid form of folate – from supplements and fortified food (Folate, 2014).

Supplementing folate
Amounts of folate/folic acid used in practice and research range from 100–5000 mcg/day in divided doses (Office of Dietary Supplements, n.d.).

A good quality multivitamin/mineral supplement typically contains 400 mcg of folate.

SAFETY, SIDE EFFECTS

  • Folate supplementation may mask an underlying vitamin B12 deficiency.
  • In order to be very sure of preventing irreversible neurological damage in vitamin B12-deficient individuals, the Food and Nutrition Board of the US Institute of Medicine advises that all adults limit their intake of folic acid (supplements and fortification) to 1000 μg (1 mg) daily (Folate, 2014).

Other actions of vitamin B12 in preventing and addressing Alzheimer’s disease include:

  • maintaining blood–brain barrier integrity – by reducing homocysteine-associated vascular injury (El-Mezayen et al., 2022)
  • protecting mitochondria from oxidative stress and amyloid-β toxicity – by scavenging reactive oxygen species (highly-reactive oxygen-containing molecules), preserving glutathione, and preventing mitochondrial dysfunction (Lauer et al., 2022)
  • regulating calcium signalling – which protects neurons from amyloid-β-induced oxidative injury (Lauer et al., 2022)
  • reducing amyloid-related damage – by preventing amyloid-β from forming harmful clumps and helping break up existing deposits (Lauer et al., 2022; Wang et al., 2023)
  • reducing tau-related damage – by preventing tau proteins from clumping together into tangles inside brain cells (Lauer et al., 2022)
  • reducing neuroinflammation – by modulating inflammatory cytokine activity (El-Mezayen et al., 2022; Lauer et al., 2022)
  • supporting neurotransmitter production, myelin formation, and neuronal communication – which helps maintain and repair neural structures (Lauer et al., 2022)

The most common causes of vitamin B12 deficiency:

  • vitamin B12-deficient diet
  • vegetarianism or veganism
  • bacterial overgrowth in the small intestine
  • increased breakdown of vitamin B12 in brain tissue (Gaby, 2011)
  • poor absorption due to decreased stomach acid production, low intrinsic factor, celiac or Crohn’s Disease, alcohol consumption, antacids

Vitamin B12 levels can be normal in blood tests but be deficient in the cerebral spinal fluid (Prousky, 2015). However most clinicians do not consider vitamin B12 to be an issue unless serum B12 levels are below laboratory reference ranges.

More information:
Prousky, (2010). Understanding the serum vitamin B12 level and its implications for treating neuropsychiatric conditions: An Orthomolecular Perspective. Journal of Orthomolecular Medicine, 25(2).

Top food sources of vitamin B12 by serving size:

  • clams, mussels
  • mackerel
  • crab
  • beef

Comprehensive food list:
Table 2. Some Food Sources of vitamin B12 (Vitamin B12, 2014)
https://lpi.oregonstate.edu/mic/vitamins/vitamin-B12

Dietary reference values
RDAs for vitamin B12 (mcg/day)
Adolescents (14-18 years): 2.4 (M) 2.4 (F)
Adults (19-50 years): 2.4 (M) 2.4 (F)
Adults (51 years and older): 2.4 (M) 2.4 (F)

Tolerable Upper Intake
Not established due to low potential for toxicity.

Supplementing vitamin B12

  1. Vitamin B12 Supplementation
  • Amounts of vitamin B12 used in practice and research range from 1,000–5,000 IU a day in divided doses.
  • The preferred form of vitamin B12 is methylcobalamin, due to its greater tissue retention (“Methylcobalamin”, 1998)
  • Vitamin B12 is best absorbed in sublingual form.
  • “Those strict vegetarians who eat no animal products (vegans) need supplemental vitamin B12 to meet their requirements” (Vitamin B12, 2014)
  1. Vitamin B12 injections
  • A typical injection regimen is 1000 mcg every 2 weeks.
  • Patients who respond to vitamin B12 injections typically need ongoing injections to maintain symptom improvement (Gaby, 2011).

SAFETY, SIDE EFFECTS

  • The Institute of Medicine states that “no adverse effects have been associated with excess vitamin B12 intake from food and supplements in healthy individuals” (Vitamin B12, 2014).

Vitamin C

Actions of vitamin C in preventing and addressing Alzheimer’s disease include:

  • reducing oxidative stress – by:
    • scavenging reactive oxygen species, which decreases oxidative damage to neurons (Dey & Singh, 2022; Marino et al., 2023)
    • increasing antioxidant capacity, which protects lipids, proteins, and DNA from injury (Marino et al., 2023)
  • binding reactive metals – which decreases free radical formation (Marino et al., 2023)
  • reducing oxidative stress in mitochondria – which supports mitochondrial function and neuronal survival (Marino et al., 2023)
  • suppressing neuroinflammation – by:
    • modulating microglial activation, which reduces pro-inflammatory signalling (Marino et al., 2023)
    • protecting synapses and neurons from inflammatory damage (Hamid et al., 2022)
  • reducing amyloid-β production – by influencing APP processing and suppressing BACE-1 activity, which decreases amyloid-β generation (Marino et al., 2023; Hamid et al., 2022)
  • inhibiting amyloid-β fibril formation – which:
    • reduces amyloid aggregation (Heo et al., 2013; Marino et al., 2023)
    • lowers neuronal toxicity (Heo et al., 2013)
  • enhancing cholinergic neurotransmission – by reducing acetylcholinesterase activity (Heo et al., 2013)
  • supporting norepinephrine synthesis – which supports attention, mood, and stress response (Hamid et al., 2022)
  • regulating glutamate signalling – which reduces excitotoxic neuronal injury (Marino et al., 2023)
  • modulating NMDA receptor activity – which stabilizes synaptic signalling (Marino et al., 2023)
  • preserving nitric oxide – by scavenging superoxide, a highly reactive oxygen species, thereby improving endothelial function (Marino et al., 2023)
  • reducing peroxynitrite formation (a highly reactive molecule formed when superoxide reacts with nitric oxide) – by preserving nitric oxide and lowering oxidative stress (Marino et al., 2023).
  • maintaining healthy cerebral blood vessels – by reducing endothelial dysfunction and oxidative injury (Marino et al., 2023; Heo et al., 2013)
  • improving nitric oxide signalling – which increases cerebral blood flow (Heo et al., 2013)
  • preventing oxidative damage to LDL cholesterol – which helps reduce inflammation and injury to blood vessels (Marino et al., 2023)
  • strengthening blood–brain barrier integrity – which limits toxin and immune cell entry (Heo et al., 2013; Marino et al., 2023)
  • supporting myelination and neuronal function – by supporting myelin formation and regulating gene expression through DNA demethylation (Marino et al., 2023)
  • protecting against aluminum-induced neurotoxicity – by reducing oxidative damage associated with aluminum exposure (Dey & Singh, 2022)

Causes of vitamin C deficiency:

  • restrictive diets
  • diet lacking in sources of vitamin C, especially fresh fruit and vegetables
  • digestive tract disorders, e.g. diarrhea, Crohn’s and colitis
  • smoking
  • alcoholism
  • chronic inflammatory conditions

Signs of vitamin C deficiency:

  • bleeding or swollen gums
  • frequent nosebleeds
  • dry hair, split ends
  • easy bruising
  • slow wound healing
  • fatigue
  • moodiness
  • depression and cognitive impairment (Plevin & Galletly, 2020)

Top sources of vitamin C based on serving size:

  • grapefruit and orange juice
  • strawberries
  • kiwifruit
  • orange
  • sweet pepper
  • broccoli

Comprehensive food list:
Table 3. Some Food Sources of vitamin C (Vitamin C, 2014)
https://lpi.oregonstate.edu/mic/vitamins/vitamin-C

Dietary reference values
RDAs for vitamin C (mg/day)
Adolescents (14-18 years): 75 (M) 65 (F)
Adults (19-50 years): 90 (M) 75 (F)
Smokers: 125 (M) 110 (F)

Tolerable Upper Intake: 2000 mg /day
(Office of Dietary Supplements – Vitamin C, n.d.)

Supplementation

  • Amounts of vitamin C used in practice and research range from 500–6000 mg/day in divided doses.
  • Studies have shown that schizophrenic patients require vitamin C supplementation in the high-gram range in order to saturate body tissue stores. (Freeman, 1973; Suboticanec, et al., 1990).”

SAFETY, SIDE EFFECTS

  • Vitamin C has low toxicity and is not believed to cause serious adverse effects at high intakes (Office of Dietary Supplements – Vitamin C, n.d.).
  • Vitamin C at higher doses can, in some people, cause side effects such as nausea, abdominal cramps, and other digestive tract disturbances

Vitamin D

Actions of vitamin D in preventing and addressing Alzheimer’s disease include:

  • suppressing pro-inflammatory signalling – by reducing pro-inflammatory cytokines and NF-κB activation, which decreases chronic brain inflammation, microglial overactivation, and neuronal damage (Cekic et al., 2009; Kouba et al., 2023)
  • enhancing anti-inflammatory signalling – by increasing IL-10, IL-4, and TGF-β, which promotes the resolution of chronic neuroinflammation (Kouba et al., 2023)
  • reducing oxidative stress – by enhancing antioxidant defenses, reducing reactive oxygen species, and activating Nrf2 signalling (Cekic et al., 2009; Kouba et al., 2023)
  • reducing amyloid-β buildup – by decreasing its production and helping the brain clear it away (Kouba et al., 2023; Lasoń et al., 2023)
  • reducing harmful tau buildup – by decreasing the formation of tau tangles, which helps slow damage to brain cells (Thiel et al., 2023)
  • reducing intracellular calcium overload – which prevents excitotoxic neuronal death (Chakkera et al., n.d.)
  • increasing neurotrophic factor expression (e.g., glial cell line-derived neurotrophic factor GDNF) – which:
    • promotes neuronal growth and survival, and supports repair after injury (Cekic et al., 2009; Lasoń et al., 2023)
    • reduces apoptosis, which preserves neuronal integrity and slows neurodegeneration (Lasoń et al., 2023)
  • supporting myelination and neuronal proliferation (Lasoń et al., 2023)
  • regulating neurotransmitter synthesis and signalling – by:
    • modulating neurotransmitter activity and balance (Thiel et al., 2023)
    • supporting synaptic plasticity and communication between neurons (Kouba et al., 2023)
    • contributing to improved cognitive function and neuronal signalling (Thiel et al., 2023)

Causes of vitamin D deficiency

  • limited sun exposure
  • strict vegan diet (most sources of vitamin D are animal-based)
  • darker skin (the pigment melanin reduces the vitamin D production by the skin)
  • digestive tract and kidney issues
  • obesity (vitamin D is sequestered by fat cells)

Measuring vitamin D
The best indicator of vitamin D status is serum 25(OH)D, also known as 25-hydroxyvitamin D. 25(OH)D reflects the amount of vitamin D in the body that is produced by the skin and obtained from food and supplements.

Vitamin D levels and health status
(Dietary Reference Intakes for Calcium and Vitamin D, 2011)
Serum (ng/ml)  and Health status
<20  deficient
20–39  generally considered adequate
40–50  adequate
50–60   proposed optimum health level
200  potentially toxic

Top sources of vitamin D based on serving size (Office of Dietary Supplements – Vitamin D, n.d.):

  • cod liver oil
  • trout
  • pink salmon
  • sardines
  • fortified cereal, milk, and orange juice
  • fortified almond, soy, and oat milks
  • egg yolk

Comprehensive food list
Table 3: Vitamin D Content of Selected Foods
https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

Dietary reference values
RDAs for vitamin D (IU/day)
Adolescents (14-18 years): 600 (M) 600 (F)
Adults (19-50 years): 600 (M) 600 (F)
Adults (51 years and older): 800 (M) 800 (F)

Tolerable Upper Intake: 4000 IU/day
(Office of Dietary Supplements – Vitamin D, n.d.)

Vitamin D supplementation

  • Amounts of vitamin D used in practice and research range from 400-14 000 IU/day (Vitamin D | Linus Pauling Institute | Oregon State University, 2014).

SAFETY, SIDE EFFECTS (Vitamin D | Linus Pauling Institute | Oregon State University, 2014)

  • “Research suggests that vitamin D toxicity is very unlikely in healthy people at intake levels lower than 10,000 IU/day”
  • Vitamin D can increase risk of hypercalcemia with calcium-related medical conditions – including primary hyperparathyroidism, sarcoidosis, tuberculosis, and lymphoma
  • Certain medical conditions can increase the risk of hypercalcemia in response to vitamin D, including primary hyperparathyroidism, sarcoidosis, tuberculosis, and lymphoma

Some drugs that affect vitamin D absorption or metabolism include (Vitamin D, 2014):

  • cholestyramine
  • colestipol
  • orlistat
  • mineral oil
  • phenytoin
  • fosphenytoin
  • phenobarbital
  • carbamazepine
  • rifampin
  • cimetidine
  • ketoconazole
  • glucocorticoids
  • HIV treatment drugs

Vitamin E

Actions of vitamin E in preventing and addressing Alzheimer’s disease include:

  • scavenging free radicals and reducing lipid peroxidation in neuronal membranes (Browne et al., 2019)
  • activating Nrf2 signalling – which enhances endogenous (produced within the body) antioxidant defenses (Wang et al., 2023)
  • protecting neurons from amyloid-β–induced oxidative damage (Ayoub et al., 2023; Wang et al., 2023)
  • regulating genes involved in oxidative stress and inflammation (Boccardi et al., 2016)
  • inhibiting COX and 5-LOX pathways – which decreases production of prostaglandins (signalling molecules) and inflammatory signalling (Lloret et al., 2019; Boccardi et al., 2016)
  • increasing the production of IL-2 (an immune signalling protein that regulates T-cell activity) – which supports immune regulation (Lloret et al., 2019)
  • strengthening the blood–brain barrier – by reducing oxidative damage in the cells lining blood vessels, increasing the proteins that keep the barrier tightly sealed (tight junctions), and restoring blood–brain barrier function after amyloid-β damage (Lam et al., 2016; Ayoub et al., 2023)
  • supporting the conditions required for effective autophagy (cellular cleanup and recycling process) – which may reduce amyloid-β accumulation (Wang et al., 2023)
  • reducing amyloid-β accumulation – by increasing amyloid-β clearance, reducing its production, and protecting against amyloid-induced toxicity (Ayoub et al., 2023; Wang et al., 2023)
  • supporting the activity of PP2A (an enzyme that removes excess phosphate groups from proteins) – which helps maintain normal tau regulation (Boccardi et al., 2016)
  • supporting cholesterol metabolism – by protecting LDL and membrane cholesterol from oxidative damage (Boccardi et al., 2016)

Causes of vitamin E deficiencies:

  • conditions that affect the digestion and absorption of fats and fat-soluble nutrients (Office of Dietary Supplements – Vitamin E, n.d.)

Vitamin E food sources
Top sources of vitamin E based on serving size:

  • sunflower seeds
  • almonds
  • sunflower oil
  • safflower oil
  • hazelnuts
  • grapeseed oil

Comprehensive food list: Table 2. Some Food Sources of Vitamin E
https://lpi.oregonstate.edu/mic/vitamins/vitamin-E

Referenced Dietary Intakes (IU/day)
Adolescents (14-18 years): 22.5 (M) 22.5 (F)
Adults (19 years and older): 22.5 (M) 22.5 (F)

Supplementation
Vitamin E supplementation

  • Amounts of vitamin E used in practice and research range from 400–2,000 IU a day in divided doses (Office of Dietary Supplements – Vitamin E, n.d.)

Choline

Choline is an essential nutrient.

Actions of choline in preventing and addressing Alzheimer’s disease include:

  • increasing acetylcholine production – which supports memory formation, attention, and cognitive processing
  • maintaining neuronal membrane integrity – by supporting phospholipid synthesis, which preserves membrane structure and signalling (Paules et al., 2025)
  • decreasing pro-inflammatory signalling in the brain – by reducing microglial activation (Dave et al., 2023)
  • reducing insulin resistance in the brain – which supports normal insulin signalling (Dave et al., 2023)
  • supporting methylation – which lowers homocysteine levels and reduces vascular damage (Choline | Linus Pauling Institute, 2014)

Causes of choline deficiencies:

  • Since some choline is synthesized by the body, overt choline deficiency is rare. However people with variations in genes involved with metabolism of folate, methionine, and choline may have an increased demand for additional dietary choline (Choline Fact Sheet for Health Professionals, n.d.).
  • Demands for choline increase during pregnancy.

Top sources of choline (based on mg/serving):

  • beef liver
  • eggs
  • beef
  • soybeans
  • chicken
  • cod
  • potatoes

Comprehensive food list
Table 2: Choline Content of Selected Foods
https://ods.od.nih.gov/factsheets/Choline-HealthProfessional/

Dietary reference values
Adequate intakes for choline (mg/day) (Choline Fact Sheet for Health Professionals, n.d.)
Adolescents (14-18 years): 550  (M) 400 (F)
Adults (19+ years): 550 (M) 425 (F)

Choline supplementation

Amounts of choline used in practice and research range from 750–6000 mg/day in divided doses (Choline, 2014).

Sources of supplemental choline include:

  • choline
  • citicholine
  • betaine
  • phosphatidyl choline
  • lecithin

SAFETY/SIDE EFFECTS
High intakes of choline (10,000–16,000 mg/day) have been associated with vomiting, excessive sweating and salivation, fishy body odour, low blood pressure, and liver toxicity (Choline Fact Sheet for Health Professionals, n.d.)

CHOLINE AND MEDICATIONS
Choline is not known to interact with any medications (Choline Fact Sheet for Health Professionals, n.d.).

Chromium

Actions of chromium in preventing and addressing Alzheimer’s disease include:

  • increasing insulin sensitivity (Akhtar & Sah, 2023) – which improves glucose uptake into neurons and supports cellular energy production
  • modulating GSK-3β activity – which may decrease tau phosphorylation and reduce neurofibrillary tangle formation (Akhtar & Sah, 2023)
  • downregulating the NF-κB pathway – which decreases pro-inflammatory cytokine production, resulting in (Akhtar & Sah, 2023):
    • reduced activation of microglia and astrocytes
    • decreased chronic neuroinflammation that drives neuronal damage
  • decreasing oxidative stress and lipid peroxidation – which (Akhtar & Sah, 2023):
    • stabilizes mitochondrial membrane potential (the electrical charge across the mitochondrial membrane that is needed to produce ATP)
    • improves mitochondrial function
    • protects neuronal membranes
    • enhances neuronal survival

Top sources of chromium based on serving size:

  • broccoli
  • green beans
  • potatoes (mashed)
  • beef
  • turkey breast

Comprehensive food list:
Table 2. Some Food Sources of Chromium (Chromium, 2014)
https://lpi.oregonstate.edu/mic/minerals/chromium

Referenced Dietary Intakes
Adequate Intakes for chromium (mcg/day)
Adolescents 14-18 years 35 (M) 24 (F)
Adults 19-50 years 35 (M) 25 (F)
Adults 51 years and older 30 (M) 20 (F)

Chromium supplementation

  • Amounts of chromium used in practice and research range from 100–1,000 mcg a day in divided doses (Office of Dietary Supplements, n.d.).

SAFETY, SIDE EFFECTS

  • The Food and Nutrition Board concluded that no adverse effects have been linked to high intakes of chromium from food or supplements, so it did not establish a UL for chromium (Office of Dietary Supplements, n.d.).

CHROMIUM AND MEDICATIONS
Chromium can interact with medication interactions including (Office of Dietary Supplements, n.d):

  • insulin
  • metformin and other antidiabetes medications
  • levothyroxine

Magnesium

Actions of magnesium in preventing and addressing Alzheimer’s disease include:

  • modulating inflammatory signalling – low magnesium status increases inflammation, while adequate magnesium helps reduce pro-inflammatory activity (Magnesium | Linus Pauling Institute, 2024)
  • enabling glutathione synthesis – which increases antioxidant capacity, and protects lipids, proteins, and DNA (Magnesium | Linus Pauling Institute, 2024)
  • improving insulin sensitivity – by helping cells respond better to insulin and use glucose more effectively, which improves glucose uptake and overall energy regulation (Hosseini Dastgerdi et al., 2022)
  • supporting ATP production – by acting as a cofactor for ATP synthesis and forming Mg-ATP, the biologically active form of cellular energy (Magnesium | Linus Pauling Institute | Oregon State University, 2014)
  • regulating NMDA receptors – by controlling how much calcium enters nerve cells during signalling and closing the channels after activation (Ben Zaken et al., 2020)
  • supporting synaptic plasticity, learning, and memory – by maintaining normal NMDA receptor signalling during excitatory neurotransmission (Ben Zaken et al., 2020)
  • reducing glutamate-driven excitotoxicity – which decreases neuronal overstimulation, calcium overload, and neuronal degeneration (Tao et al., 2022)
  • improving endothelial function – by regulating nitric oxide production and endothelial cell activity, which supports vascular function and blood flow (Fatima et al., 2024)

Reasons for magnesium deficiencies include:

  • increased stress (causes magnesium depletion)
  • low dietary protein (needed for magnesium absorption)
  • gastrointestinal disorders (e.g. Crohn’s disease, malabsorption syndromes, and prolonged diarrhea)
  • high doses of supplemental zinc (competes for absorption)
  • certain diuretic medications
  • alcoholism
  • age – elderly adults tend to have lower dietary intake, absorption, and increased loss of magnesium

Top food sources of magnesium by serving size:

  • Brazil nuts
  • oat bran
  • brown rice (whole grain)
  • mackerel

Comprehensive list: Table 2. Some Food Sources of Magnesium
(Magnesium, 2014)
https://lpi.oregonstate.edu/mic/minerals/magnesium

Referenced Dietary Intakes
RDAs for magnesium (mg/day)
Adolescents (14-18 years): 410 (M) 360 (F)
Adults (19-30 years): 400 (M) 310 (F)
Adults (31 years and older): 420 (M) 320 (F)

Magnesium supplementation

  • The effect of magnesium on blood pressure is dose-dependent (Houston & Harper, 2008; Jee et al., 2002).
  • Kass et al. (2012) identified magnesium dosing in studies ranging from 120–973 mg/day, with an average dose of 410 mg/day, and a greater effect in doses greater than or equal to 370 mg/day.

SAFETY, SIDE EFFECTS

  • Side effects of magnesium supplementation are rare but can include a laxative effect, dizziness or faintness, sluggishness, cognitive impairment, and depression.

Selenium

  • enabling the activity of antioxidant selenoenzymes (e.g., glutathione peroxidase and thioredoxin reductase) – which scavenge reactive oxygen species; reduce lipid, protein, and DNA damage; and protect neurons from oxidative injury and death (Gireadă et al., 2022; Pereira et al., 2022)
  • reducing pro-inflammatory cytokine signalling – which suppresses neuroinflammation (Pereira et al., 2022; Gireadă et al., 2022).
  • supporting mitochondrial function – by increasing ATP production and reducing mitochondrial reactive oxygen species (Zhang et al., 2023)
  • reducing the interaction of copper and iron with amyloid-β – which decreases amyloid toxicity (Gireadă et al., 2022; Zhang et al., 2023)
  • decreasing β-secretase and γ-secretase activity – which reduces amyloid-β production (Gireadă et al., 2022; Zhang et al., 2023)
  • inhibiting the activity of the enzyme GSK-3β – which decreases tau hyperphosphorylation and neurofibrillary tangle formation (Gireadă et al., 2022; Zhang et al., 2023)
  • reducing tau aggregation – through the activity of intracellular antioxidant selenoenzymes (including glutathione peroxidase and thioredoxin reductase) (Gireadă et al., 2022)
  • activating FoxO signalling pathways – which support memory consolidation and synaptic function (Zhang et al., 2023)
  • enhancing synaptic function – by increasing the expression of synaptic proteins involved in synapse structure and signalling (including PSD95 and synaptophysin), thereby supporting communication between neurons (Zhang et al., 2023)

Selenium deficiency

  • Inadequate intake of selenium is widespread in many parts of the world (Gröber & Holick, 2022), including in Western countries (Iddir et al., 2020).
  • Issues with liver function can contribute to decreased production of selenoproteins (Erol et al., 2021).
  • Selenium levels are known to be lower in people with obesity (Bermano et al., 2021).

Top sources of selenium based on serving size:

  • Brazil nuts
  • tuna, halibut, salmon
  • oysters, clams, shrimp
  • pork, beef, chicken

Comprehensive food list: Table 2. Some Common Food Sources of Selenium
https://lpi.oregonstate.edu/mic/minerals/selenium

The amount of selenium in foods is dependent on the amount of selenium in the soil in which they are grown (Khatiwada & Subedi, 2021; Bermano et al., 2021).

Referenced Dietary Intakes
RDAs for selenium (mcg/day)
Adolescents (14-18 years): 55 (M) 55 (F)
Adults (19 years and older): 55 (M) 55 (F)

The RDA values represent intakes from food and supplement sources.

Selenium supplementation

  • Amounts of selenium used in practice and research range from 100–300 mcg a day in divided doses (Office of Dietary Supplements – Selenium, n.d.).
  • Selenium supplements ranging from 10 to 300 mcg/day have been given to healthy populations for periods ranging from 3 months to 12 months. (Drutel et al., 2013).
  • Consumption of 100 micrograms a day of selenium is required for optimal function of the most important selenoproteins (Alexander et al., 2020).

Common forms of selenium supplements

  • selenium yeast, selenium-enriched yeast
  • sodium selenite
  • selenomethionine (highly absorbable form)

SAFETY, SIDE EFFECTS

  • Although normally safe, high-dose selenium supplementation may have negative effects for people who already have sufficient dietary selenium intake (Gröber & Holick, 2022).
  • Doses ranging from 100–600 mcg/day have not shown any toxic reactions (Berger et al., 2001).
  • Selenium toxicity is seen at levels above 750–800 mcg/day (Berger et al., 2001).
  • Long-term intakes of selenium in excess of 300 mcg/day from food and supplements may be associated with toxicity (Alexander et al., 2020).
  • Indicators of excess selenium intake include (Office of Dietary Supplements – Selenium, n.d.) garlic odour in the breath and a metallic taste in the mouth, brittleness or loss of hair or nails.
  • Monitoring of selenium blood levels is recommended with prolonged high-dose supplementation (Khatiwada & Subedi, 2021).

SELENIUM AND MEDICATIONS

  • IMPORTANT: thyroid medication dosing may need to adjusted when taking selenium in response to an increase in body production of thyroid hormones.

Zinc

Actions of zinc in preventing and addressing Alzheimer’s disease include:

  • supporting antioxidant enzyme activity – by serving as a cofactor for copper-zinc superoxide dismutase (Cu/Zn SOD), which reduces oxidative damage to neurons (Zinc | Linus Pauling Institute | Oregon State University, 2014)
  • reducing amyloid-β buildup – by decreasing its formation and supporting zinc-dependent enzymes that help break down and clear amyloid-β (Rivers-Auty et al., 2021)
  • promoting neuronal survival and synaptic plasticity – by supporting zinc-dependent enzymes such as MMP-9 (Rivers-Auty et al., 2021) that activate brain-derived neurotrophic factor (BDNF)
  • supporting copper-zinc balance – which helps limit inflammation and oxidative stress associated with neurodegenerative processes (Escobedo-Monge et al., 2021)

Zinc deficiency:

  • is common in the elderly (Gröber & Holick, 2022) with almost half of older populations having inadequate intake (Sestili & Fimognari, 2020)
  • is increased in those avoiding red meat, vegans, and people in developing countries who consume a mainly plant-based diet (Gammoh & Rink, 2017)
  • ranges from 15% to 31% in developed countries (Vogel-González et al., 2021)

Zinc requirements are increased:

  • during or severe infections, stress, and trauma (Gammoh & Rink, 2017)
  • in the elderly, infants, and alcoholics (Pal et al., 2021)
  • Zinc deficiency increases susceptibility to a variety of infections (Sestili & Fimognari, 2020); Iddir et al., 2020).

Top sources of zinc based on serving size:

  • oyster, cooked
  • beef, chuck, blade roast, cooked
  • beef, ground, 90% lean meat, cooked
  • crab, Dungeness, cooked
  • fortified, whole-grain toasted oat cereal

Comprehensive food list:
Table 2. Some Food Sources of Zinc
https://lpi.oregonstate.edu/mic/minerals/zinc

Referenced Dietary Intakes
RDAs for zinc (mg/day)
Adolescents 14-18 years: 11 (M) 9 (F)
Adults 19 years and older: 11 (M) 8 (F)

Supplementing Zinc

  • Amounts of zinc used in practice and research range from 10–200 mg a day in divided doses (Zinc, 2014).
  • “Long-term zinc supplementation should be accompanied by a copper supplement (1–4 mg/day, depending on the zinc dose), in order to prevent zinc-induced copper deficiency” (Gaby, 2011)

SAFETY, SIDE EFFECTS

  • High zinc intakes can inhibit copper absorption, sometimes producing copper deficiency and associated anemia (Office of Dietary Supplements – Zinc, 2014).
  • Intakes of zinc should not exceed the UL (40 mg/day for adults) in order to limit the risk of copper deficiency in particular
  • Milder gastrointestinal distress has been reported at doses of 50 to 150 mg/day of supplemental zinc (Zinc, 2014).

Omega-3 fatty acids

Actions of omega-3 fatty acids in preventing and addressing Alzheimer’s disease include:

  • reducing oxidative stress (Huang et al., 2022)
  • suppressing neuroinflammation – by reducing pro-inflammatory cytokines and microglial activation (Huang et al., 2022)
  • reducing thrombosis (blood clot formation) – which may improve cerebral blood flow and oxygen delivery to brain tissue (Huang et al., 2022)
  • promoting neurogenesis – which supports neuronal repair and brain function (Huang et al., 2022)
  • enhancing macrophage energy production and phagocytosis – which promotes immune-mediated clearance of amyloid-beta and cellular debris (Lau et al., 2020)
  • promoting AQP4-mediated glymphatic clearance – which enhances removal of amyloid-beta from the brain (Lau et al., 2020)
  • supporting proteostasis – the process which maintains protein quality control and reduces the accumulation of misfolded proteins, including amyloid-beta (Lau et al., 2020)

Reasons for omega-3 fatty acid deficiencies:

  • inadequate dietary intake
  • poor absorption
  • deficiencies of nutrients required for EFA metabolism
  • issues with metabolism that cause decreased incorporation of, or increased removal of, fatty acids from cell membranes

Top EPA and DHA (animal-derived omega 3) food sources by serving size:

  • herring, pacific
  • salmon, chinook
  • sardines, pacific
  • salmon, atlantic
  • oysters, pacific

Comprehensive food list:
Table 4. Food Sources of EPA (20:5n-3) and DHA (22:6n-3) (Office of Dietary Supplements, n.d.)
https://lpi.oregonstate.edu/mic/other-nutrients/essential-fatty-acids

Top alpha-linolenic acid (plant-derived omega 3) food sources by serving size

  • flax seed oil
  • chia seeds
  • walnuts
  • flax seeds ground

Comprehensive food list:
Table 3. Food Sources of α-Linolenic Acid (18:3n-3) (Office of Dietary Supplements, n.d.)
https://lpi.oregonstate.edu/mic/other-nutrients/essential-fatty-acids

Referenced Dietary Intakes
Adequate Intakes for alpha-linolenic acid (plant-derived omega 3) (g/day) (Dietary Reference Intakes for Energy, n.d.)
Adolescents 14–18 years: 1.6 (M) 1.1 (F)
Adults: ≥ 19 years:  1.6 (M) 1.1 (F)

Recommendations for long-chain omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (mg/day) (Authority (EFSA), 2009)
Adults:  250 (M+F)

Supplementing omega 3 fatty acids

  • Amounts of omega 3 fatty acids used in practice and research range from 1–4 g/day of combined EPA and DHA, in divided doses.
  • Fish oil and E-EPA are generally well tolerated, but may cause gastrointestinal side effects in some individuals (Gaby, 2011)
  • Long-term supplementation with EPA and DHA should be accompanied by a vitamin E supplement (Gaby, 2011), as polyunsaturated fatty acids increase vitamin E requirements in the body.

SAFETY, SIDE EFFECTS

  • Common side effects of high dose EPA and DHA supplementation include heartburn, nausea, gastrointestinal discomfort, diarrhea, headache, and odoriferous sweat
  • The European Food Safety Authority considers long-term consumption of EPA and DHA supplements at combined doses of up to about 5 g/day to be safe (Authority (EFSA), 2009).
  • The FDA recommends not exceeding 3 g/day EPA and DHA combined, with up to 2 g/day from dietary supplements (Office of Dietary Supplements, n.d.).

OMEGA 3 FATTY ACIDS AND MEDICATIONS

  • Use caution when supplementing omega 3 fatty acids while taking blood-thinning medications, or blood-sugar issues (Essential fatty acids, 2014)

Short-chain fatty acids

Short-chain fatty acids (SCFAs) are produced primarily in the large intestine when beneficial bacteria ferment dietary fibre and resistant starches.

The three principal short-chain fatty acids—acetate, propionate, and butyrate—influence several processes important for brain health. Although each have supportive actions, butyrate has shown the strongest evidence for therapeutic potential in neurodegenerative disorders (Chakraborty et al., 2024).

Actions of short-chain fatty acids in preventing and addressing Alzheimer’s disease include:

  • suppressing neuroinflammation – by (Fernando et al., 2019; Chen et al., 2022):
    • activating GPR43 (FFAR2) and FFAR3 receptors
    • reducing microglial activation
    • decreasing inflammatory cytokine production
    • shifting microglia toward an anti-inflammatory state
  • promoting the resolution of inflammation – by increasing regulatory T cells (immune cells that calm inflammation) and removing neutrophils (inflammatory immune cells) when they are no longer needed (Chen et al., 2022)
  • strengthening the blood–brain barrier – by increasing tight junction proteins and reducing inflammation and oxidative stress (Chen et al., 2022)
  • suppressing pathways involved in amyloid-beta formation – which decreases plaque development (Chen et al., 2022)
  • enhancing the intestinal hormone glucagon-like peptide-1 (GLP-1) signalling – which supports neuronal survival and helps protect neurons from amyloid-beta toxicity (Chen et al., 2022)
  • improving glucose metabolism and mitochondrial function – which increases cellular energy production and reduces metabolic stress (Chen et al., 2022)
  • inhibiting histone deacetylases (enzymes) – which restores expression of genes involved in neuronal survival, learning, and memory (Chen et al., 2022)
  • increasing the expression of BDNF and GDNF (neurotrophic signalling proteins) – which supports synaptic function, memory, and neuronal survival (Fernando et al., 2019; Chen et al., 2022)

Factors that can reduce SCFA production (Banasiewicz et al., 2020; Mukhopadhya & Louis, 2025):

  • low intake of fermentable fibre, resistant starch, and prebiotic foods
  • dysbiosis or reduced diversity of the gut microbiota
  • frequent antibiotic use
  • highly processed diets
  • gastrointestinal disorders that impair fermentation
  • rapid gut transit time
  • altered gut conditions (e.g., abnormal intestinal pH)
  • chronic stress and inflammation

Short-chain fatty acid food sources

Foods rich in resistant starches and soluble fibre help support the production of short-chain fatty acids in the colon (Banasiewicz et al., 2020; Butyric Acid, 2019).

Foods that support short-chain fatty acid production include (Butyric Acid, 2019):

  • oat bran
  • legumes
  • cooked and cooled potatoes
  • cooked and cooled rice
  • green bananas
  • apples
  • onions
  • garlic
  • asparagus
  • artichokes

Butyrate

Foods rich in fibres that may particularly support butyrate production include:

  • oats
  • rye
  • wheat bran

Foods containing naturally occurring butyrate include:

  • butter
  • whole milk
  • parmesan cheese
  • goat cheese

Short-chain fatty acid supplementation

  • Butyrate is the most commonly supplemented short-chain fatty acid.
  • Clinical studies have used oral butyrate doses ranging from approximately 150 mg/day to 2,000–4,000 mg/day, although commercial supplements commonly provide lower amounts (Banasiewicz et al., 2020).
  • 150–300 mg/day is the most common dosage recommendation for currently available butyric acid products (Banasiewicz et al., 2020).

SAFETY, SIDE EFFECTS

  • Short-chain fatty acid supplementation is generally well tolerated (Caban et al., 2026).
  • Possible side effects include bloating, gas, abdominal discomfort, nausea, and diarrhea (Caban et al., 2026).
  • Gradual dose titration may improve tolerance in sensitive individuals (Caban et al., 2026).

Clinical studies using oral butyrate doses up to approximately 2,000 mg/day have generally reported good tolerability and few adverse effects (Banasiewicz et al., 2020).

Individuals who are pregnant or breastfeeding should consult a qualified healthcare practitioner before using supplemental butyrate products.

SHORT-CHAIN FATTY ACIDS AND MEDICATIONS

  • No major medication interactions have been well established (Banasiewicz et al., 2020).
  • Antibiotic use may reduce endogenous SCFA production through disruption of the intestinal microbiota (Banasiewicz et al., 2020).
  • Individuals undergoing intensive gastrointestinal or immunosuppressive treatment should consult a healthcare practitioner before supplementation.

Medium-chain fatty acids

Medium-chain fatty acids (MCFAs) are saturated fatty acids typically containing 6–12 carbon atoms, and include caproic acid, caprylic acid, capric acid, and lauric acid.
Compared with long-chain fatty acids, MCFAs are absorbed and metabolized more rapidly due to their shorter chain length.

Actions of medium-chain fatty acids in preventing and addressing Alzheimer’s disease include:

  • increasing ketone availability to the brain – by generating ketone bodies that bypass impaired cerebral glucose metabolism and provide an alternative fuel for neuronal ATP production (Castro et al., 2023)
  • improving mitochondrial function – by helping mitochondria produce energy more efficiently and supporting the brain’s energy needs (Castro et al., 2023)
  • protecting against oxidative stress – by limiting oxidative damage to lipids, proteins, and DNA (Castro et al., 2023)
  • suppressing neuroinflammation – by reducing microglial activation and pro-inflammatory cytokine production (Lilamand et al., 2021)

Reasons for inadequate intake or altered utilization of medium-chain fatty acids include, (Jadhav & Annapure, 2023; Augustin et al., 2018):

  • low dietary intake of foods naturally containing medium-chain triglycerides, from which medium-chain fatty acids are released during digestion
  • fat malabsorption syndromes
  • pancreatic insufficiency
  • gastrointestinal disorders affecting fat digestion or absorption
  • gastrointestinal surgery affecting digestion or absorption

Foods naturally containing medium-chain triglycerides include (Jadhav & Annapure, 2023):

  • coconut oil
  • palm kernel oil
  • whole milk
  • butter
  • cheese
  • goat milk

Medium chain fatty acids can also be obtained from commercial medium-chain triglyceride (MCT) oils which are typically derived from coconut oil or palm kernel oil.

Human breast milk is also a natural source of medium-chain triglycerides.

Medium-chain triglyceride (MCT) supplementation

Most clinical and nutritional research has been conducted using medium-chain triglycerides (MCTs), rather than isolated MCFA.

  • Typical doses used in studies range from approximately 5–50 g/day in divided doses (Jadhav & Annapure, 2023; Augustin et al., 2018).
  • Many studies use ~20 g/day as a standard intervention dose (Avgerinos et al., 2020).
  • Higher intakes (up to ~1 g/kg body weight/day) have been investigated in neurological and ketogenic contexts (Heidt et al., 2026).

Gastrointestinal tolerance can be improved by (Heidt et al., 2026):

  • dividing doses throughout the day
  • starting with lower doses and gradually increasing
  • taking MCTs with food (although this may slightly reduce ketogenic response in some contexts)

SAFETY, SIDE EFFECTS

  • MCTs are generally well tolerated in healthy individuals (Jadhav & Annapure, 2023).
  • Gradual titration improves tolerability in most individuals.
  • Side effects are dose-dependent and may include nausea, abdominal cramping, bloating, flatulence, and diarrhea or loose stools. These effects are more likely with rapid dose escalation or high single doses.

MEDIUM-CHAIN FATTY ACIDS AND MEDICATIONS

  • Individuals using ketogenic therapies or glucose-lowering medications, or with significant liver disease should seek medical supervision before use.

Acetyl-L-carnitine (ALCAR)

Acetyl-L-carnitine (ALCAR) is a naturally occurring compound formed from acetyl-CoA and L-carnitine.

ALCAR is commonly used in neurological and metabolic contexts due to its ability to cross the blood–brain barrier and participate in mitochondrial energy metabolism (Bigio et al., 2024).

Actions of ALCAR in preventing and addressing Alzheimer’s disease include:

  • increasing neuronal ATP production – which improves cellular function and helps counter the energy deficits associated with Alzheimer’s disease (Pennisi et al., 2020)
  • stabilizing neuronal membranes and synapses – which improves membrane function, enhances communication between neurons, and supports cognitive processing (Pennisi et al., 2020)
  • improving acetylcholine signalling – which supports memory, learning, attention, and cognitive function (Pennisi et al., 2020)
  • supporting neuronal growth and survival – by enhancing neurotrophic signalling (Pennisi et al., 2020)
  • reducing oxidative stress – which helps protect neurons from free radical damage and neurodegeneration (Pennisi et al., 2020)
  • reducing excitotoxicity – which helps protect neurons from degeneration (Pennisi et al., 2020)

Causes of carnitine insufficiency

L-carnitine is synthesized primarily in the liver and kidneys from the amino acids lysine and methionine. It can also be obtained from dietary sources, particularly meat and dairy products (Office of Dietary Supplements – Carnitine, n.d.).

Because acetyl-L-carnitine is produced from L-carnitine, its levels are influenced by the availability of carnitine (Office of Dietary Supplements – Carnitine, n.d.).

Causes of reduced carnitine status or increased requirement include (Office of Dietary Supplements – Carnitine, n.d.):

  • low intake of animal-source foods (e.g., strict vegan diets)
  • increased metabolic demand in illness or catabolic states
  • chronic kidney disease or dialysis
  • inherited disorders of carnitine transport
  • use of certain medications (e.g., pivalate-containing antibiotics, valproic acid)

Carnitine food sources

Carnitine is found primarily in animal foods. These dietary sources provide L-carnitine, which contributes to the body’s overall carnitine pool.

Dietary sources of carnitine include (Office of Dietary Supplements – Carnitine, n.d.):

  • beef steak
  • ground beef
  • milk, whole
  • codfish
  • chicken breast
  • cheese, cheddar
  • whole-wheat bread
  • asparagus

Typical dietary intake (Office of Dietary Supplements – Carnitine, n.d.):

  • omnivorous diet: ~24–145 mg/day
  • vegan diet: ~1–2 mg/day

Vegetables, fruits, and grains generally contain negligible amounts of carnitine.

Acetyl-L-carnitine supplementation

  • Amounts of acetyl-L-carnitine used in practice and research range from 1–3 g/day in divided doses (Pennisi et al., 2020).

SAFETY, SIDE EFFECTS

Doses up to approximately 3 g/day have generally been well tolerated in clinical studies, including short-term use in older adults without significant changes in standard blood chemistry (Office of Dietary Supplements – Carnitine, n.d.).

Reported side effects include (Office of Dietary Supplements – Carnitine, n.d.):

  • nausea
  • vomiting
  • abdominal discomfort
  • agitation or restlessness
  • confusion (rare)

ACETYL-L-CARNITINE AND MEDICATIONS

Potential interactions include (Office of Dietary Supplements – Carnitine, n.d.):

  • valproic acid and other anticonvulsants (may reduce carnitine levels)
  • pivalate-containing antibiotics (may increase carnitine loss)

Caution is advised in individuals with seizure disorders or significant renal impairment (Office of Dietary Supplements – Carnitine, n.d.).

Alpha-lipoic acid

Alpha-lipoic acid (ALA) is a naturally occurring compound synthesized in human mitochondria and functions as a cofactor in key enzymatic reactions involved in energy metabolism.

Actions of alpha-lipoic acid in preventing and addressing Alzheimer's disease include:

  • removing harmful reactive oxygen species (ROS) and binding metal ions – which reduces oxidative stress and inhibits the formation of highly damaging hydroxyl radicals (Lam et al., 2016; Dey & Singh, 2022)
  • supporting glutathione-dependent antioxidant defenses – by increasing reduced glutathione levels, which enhances protection against oxidative damage (Brown, 2017; Lam et al., 2016)
  • suppressing neuroinflammation – which helps reduce ongoing neuronal damage (Brown, 2017; Lam et al., 2016)
  • preserving blood–brain barrier integrity – by reducing oxidative stress and neuroinflammation (Lam et al., 2016)
  • supporting mitochondrial function and cellular energy production (Brown, 2017)
  • improving communication between brain cells – by increasing the production of acetylcholine (a neurotransmitter important for learning and memory) and enhancing its signalling (Dey & Singh, 2022; Brown, 2017; Lam et al., 2016)

Alpha-lipoic acid food sources (Fogacci et al., 2020)

Animal tissues sources (higher content):

  • liver
  • kidney
  • heart

Vegetable sources include:

  • spinach
  • broccoli
  • tomatoes
  • peas
  • Brussels sprouts
  • rice bran

Alpha-lipoic acid supplementation

  • Amounts of alpha lipoic acid used in practice and research range from 200–1,800 mg/day in divided doses (Salehi et al., 2019).

SAFETY, SIDE EFFECTS

Alpha-lipoic acid is generally considered safe at commonly used supplemental doses (Fogacci et al., 2020).

Reported side effects include (Fogacci et al., 2020):

  • nausea
  • vomiting
  • dyspepsia or gastrointestinal discomfort
  • headache (less common)
  • hypoglycemia

Caution is advised in (Salehi et al., 2019):

  • individuals taking multiple glucose-lowering or metabolic medications
  • older adults on multiple metabolic medications
  • individuals with thyroid disorders
  • chronic alcohol use, especially if associated with thiamine deficiency
  • suspected or known thiamine deficiency

ALPHA-LIPOIC ACID AND MEDICATIONS

Potential interactions include (Salehi et al., 2019):

  • anti-diabetic medications and insulin (additive hypoglycemic effect)
  • possible interaction with thyroid-related therapies
  • theoretical concerns in individuals with thiamine deficiency

Curcumin

Curcumin is a substance that comes from the plant Curcuma longa – which is commonly called commonly called turmeric.

Actions of curcumin in preventing and addressing Alzheimer’s disease include:

  • protecting neurons from oxidative stress – by activating the Nrf2/ARE pathway (which switches on the body’s antioxidant defenses), and increasing the production of protective antioxidants (Wang et al., 2023)
  • regulating nitric oxide signalling – which reduces oxidative injury and supports neuronal survival (Wang et al., 2023)
  • enhancing DNA repair – which limits cumulative neuronal damage (Wang et al., 2023)
  • maintaining healthy calcium levels inside brain cells – which helps prevent calcium overload, reduces damage caused by overactive nerve signalling, and protects brain cells (Wang et al., 2023)
  • inhibiting the formation of neurofibrillary tangles and BACE1 activity – which reduces amyloid plaque development and amyloid-induced neurotoxicity (Dey & Singh, 2022; Wang et al., 2023)
  • suppressing GSK3β activity – which further limits the formation of neurofibrillary tangles (Wang et al., 2023)

Curcumin is found mainly in turmeric and foods containing turmeric.

Food sources include:

  • turmeric root (fresh or dried)
  • curry powders (amount of curcumin varies widely)
  • spice blends containing turmeric

Turmeric composition (Ahmad et al., 2020; Kunnumakkara et al., 2023):

  • curcuminoids make up ~2–9% of turmeric
  • curcumin is the main curcuminoid (~75%)

Because turmeric is used in small culinary amounts, dietary intake of curcumin is generally low.

Curcumin is available as a dietary supplement in much higher amounts than would be obtained from food.

Curcumin is poorly absorbed from the digestive tract. Different supplemental forms can improve absorption, including (Hewlings & Kalman, 2017; Hegde et al., 2023; Kunnumakkara et al., 2023):

  • curcumin with piperine (from black pepper)
  • fat-based or lipid formulations
  • specialised delivery systems (e.g., micelles or phospholipids)

Typical doses used in human studies (Hewlings & Kalman, 2017; Kunnumakkara et al., 2023):

  • about 500 mg to 3,000 mg per day in divided doses
  • higher single doses (up to about 12 g) have been used short-term and were generally well tolerated

SAFETY, SIDE EFFECTS

Curcumin is generally well tolerated in human studies. Possible side effects, usually mild, include (Hewlings & Kalman, 2017; Kunnumakkara et al., 2023):

  • stomach upset or indigestion
  • nausea
  • diarrhea
  • headache
  • yellow colouring of stool

Higher doses or taking curcumin on an empty stomach may increase digestive side effects in some people.

CURCUMIN AND MEDICATIONS

  • Curcumin may interact with certain medications, especially when taken in concentrated supplement form (Volak et al., 2008).
  • Curcumin may have mild effects on blood clotting. This could increase the effect of blood thinning medications such as aspirin, clopidogrel, warfarin, heparin and related anticoagulants (Hussain et al., 2022).
  • Curcumin (and especially curcumin combined with black pepper extract) may affect how the body breaks down certain medications by influencing liver enzymes and transport systems. This could potentially change how long some drugs stay active in the body (Volak et al., 2008).

Melatonin

Actions of melatonin in preventing and addressing Alzheimer’s disease include:

  • scavenging free radicals, reducing lipid peroxidation, and enhancing endogenous antioxidant defenses – which limits oxidative neuronal injury (Dey & Singh, 2022; Rao et al., 2023)
  • preserving mitochondrial function – which supports neuronal energy production and helps maintain normal cellular function (Lam et al., 2016; Rao et al., 2023)
  • inhibiting NF-κB signalling, reducing pro-inflammatory cytokine production, and suppressing astrocyte activation – which limits inflammatory neuronal damage (Roy et al., 2022)
  • maintaining blood–brain barrier integrity – which limits the entry of toxins and inflammatory molecules into the brain (Lam et al., 2016)
  • inhibiting amyloid-β production and aggregation – which reduces plaque formation and amyloid-induced neurotoxicity (Dey & Singh, 2022; Roy et al., 2022)
  • modulating GSK-3β and PP2A activity – which limits neurofibrillary tangle formation (Dey & Singh, 2022; Roy et al., 2022)
  • regulating apoptosis pathways – which decreases programmed neuronal death (Roy et al., 2022; Lam et al., 2016)
  • promoting neuroplasticity and synaptic plasticity – by improving dendritic structure, neuronal morphology, and synaptic density (Roy et al., 2022)

Causes of melatonin deficiency:

  • light exposure at night
  • elevated cortisol (stress)
  • low amounts of dietary tryptophan
  • nutrient deficiencies that result in decreased conversion of tryptophan to serotonin, or serotonin to melatonin
  • age, as melatonin levels decrease with age (Xie et al., 2017)

Top food sources of melatonin (Meng et al., 2017):

  • salmon
  • chicken
  • pork
  • milk
  • strawberries, cherries, cranberries
  • tomatoes

Comprehensive food list: Table 1 Concentration of melatonin in food.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409706/

Supplementation

Amounts of melatonin used in practice and research range from 2–20 mg a day in divided doses (Malhotra et al., 2004)

Melatonin supplementation:

  • is well-tolerated (Xie et al., 2017)
  • has no short or long-term adverse effects (Xie et al., 2017)
  • does not promote tolerance with ongoing use (Ferracioli-Oda et al., 2013)
  • is not associated with habituation (Ferracioli-Oda et al., 2013)

In a dose-escalation study to assess melatonin safety and efficacy, healthy volunteers were given melatonin doses of 20, 30, 50, or 100 mg. The doses were well tolerated, and no safety concerns were seen (Galley et al., 2014).

Resveratrol

Resveratrol is a natural plant compound (a phytochemical) found in a variety of plant foods.

Actions of resveratrol in preventing and addressing Alzheimer’s disease include:

  • activating the enzyme SIRT-1 – which contributes to improved cerebrovascular function and suppresses pro-inflammatory signalling (Xu Lou et al., 2023; Dhapola et al., 2023)
  • activating the enzyme AMPK – which supports cellular energy metabolism (Dhapola et al., 2023)
  • inhibiting the NLRP3 inflammasome and reducing microglial and astrocyte activation (Norwitz et al., 2021) – which helps limit chronic neuroinflammation, neuronal damage, and synaptic dysfunction
  • improving cerebrovascular function and reducing vascular inflammation (Xu Lou et al., 2023)
  • improving cellular energy metabolism – by supporting healthy glucose metabolism, increasing neuronal energy availability, and reducing metabolic stress associated with cognitive decline (Dhapola et al., 2023)
  • protecting neurons in people with the APOE ε4 genetic variant – by helping prevent metabolic crisis when both glucose and lipid metabolism are impaired (Norwitz et al., 2021)

Key dietary sources of resveratrol include (Abu-Amero et al., 2016):

  • grapes (especially grape skins)
  • red wine and grape juice
  • berries, including blueberries, cranberries, and bilberries
  • peanuts and pistachios
  • cocoa (trace amounts)

Resveratrol supplementation

  • Amounts of resveratrol used in practice and research range from 100–2,000 mg/day in divided doses (Brown et al., 2024).

SAFETY, SIDE EFFECTS

Resveratrol is generally well tolerated in human studies at typical supplemental doses. Reported adverse effects, particularly at higher supplemental doses, include nausea, abdominal discomfort, flatulence, and diarrhea. These effects are generally mild and dose-related (Brown et al., 2024).

RESVERATROL AND MEDICATIONS

Resveratrol may interact with certain medications including:

  • anticoagulant and antiplatelet drugs: theoretical increased bleeding risk due to inhibition of platelet aggregation (Shaito et al., 2020)
  • drug-metabolising enzymes (CYP450 system): potential to alter metabolism of medications processed via CYP pathways, including CYP3A4 substrates (Shaito et al., 2020)

Probiotics

Probiotics are specific live bacteria and yeasts that have beneficial effects on the body.

Actions of probiotics in preventing and addressing Alzheimer’s disease include:

  • regulating gut microbiota composition – which suppresses systemic inflammation through the gut-brain axis and may reduce amyloid-β accumulation (Bhratee et al., 2023; Romanenko et al., 2021)
  • strengthening gut barrier integrity – which reduces intestinal permeability (Romanenko et al., 2021)
  • supporting short-chain fatty acid (SCFA) production by supporting a healthy balance of gut bacteria (Romanenko et al., 2021)
  • regulating cognition-related nutrients and the metabolism of dietary polyphenols – which supports brain health and delays neurodegeneration (Romanenko et al., 2021)
  • increasing production of neurotransmitters such as GABA and influencing vagal and endocrine signalling – which supports cognitive function (Bhratee et al., 2023)
  • regulating BDNF, dopamine, serotonin, and GABA – which supports neuronal survival, synaptic plasticity, cognitive function, and behaviour (Maccioni et al., 2022)
  • enhancing insulin sensitivity and lipid metabolism – which supports cerebral energy metabolism and cognitive function (Vinuesa et al., 2021)

Probiotics are found in fermented foods that contain live microorganisms at the time of consumption.

Common sources include (Marco et al., 2017; Marco et al., 2021):

  • yogurt
  • kefir
  • sauerkraut
  • kimchi
  • miso
  • tempeh
  • some fermented cheeses and buttermilk
  • kombucha (varies depending on processing)

Not all fermented foods contain live organisms when eaten, as processing, heat, and storage conditions can reduce or eliminate viable microbes.

Probiotic supplementation

Probiotic supplements contain defined strains of live microorganisms, most commonly (Sanders et al., 2018):

  • Lactobacillus / Lacticaseibacillus species
  • Bifidobacterium species
  • Saccharomyces boulardii (yeast)

Probiotic supplements are marketed in several forms, including capsules, powders, tablets, and some liquid preparations.

SAFETY, SIDE EFFECTS

In generally healthy individuals, probiotics are well tolerated (Ryan & Patno, 2021).

Common side effects include (Ryan & Patno, 2021):

  • mild gas and bloating
  • changes in bowel habits

PROBIOTICS AND MEDICATIONS

  • Probiotics may interact indirectly with medications through effects on gut metabolism and immune function (Merenstein et al., n.d.).
  • Some antibiotics can reduce the viability of susceptible bacterial probiotic strains (Gueimonde et al., 2013)
  • There is an increased risk of infection among severely immunocompromised patients receiving immunosuppressive therapies (Kelesidis & Pothoulakis, 2012; Katkowska et al., 2021)

Coenzyme Q10 (CoQ10)

CoQ10 is a mitochondrial cofactor and lipid-soluble antioxidant that plays an essential role in cellular energy production.

Actions of CoQ10 in preventing and addressing Alzheimer’s disease include (Fišar & Hroudová, 2024; Bagheri et al., 2023):

  • supporting mitochondrial electron transport and ATP production – which helps maintain cellular energy levels.
  • preserving mitochondrial integrity – by protecting mitochondrial membranes and promoting the formation of new mitochondria
  • reducing oxidative stress – by scavenging reactive oxygen species, limiting lipid peroxidation, and regenerating vitamin E
  • maintaining healthy calcium levels inside brain cells – which helps keep mitochondria functioning properly and protects brain cells from damage and death.
  • reducing neuroinflammation
  • reducing neuronal apoptosis
  • supporting cholinergic neurotransmission
  • supporting autophagy – which may facilitate the removal of damaged cellular components and protein aggregates
  • reducing amyloid-β and tau pathology

Causes of coenzyme Q10 deficiencies

Lower CoQ10 levels may occur with:

  • increasing age (natural CoQ10 production gradually declines)
  • rare inherited disorders affecting CoQ10 production
  • certain mitochondrial diseases
  • some chronic medical conditions, including heart failure and neurodegenerative diseases
  • use of statin medications, which can reduce the body’s natural production of CoQ10

Top sources of CoQ10 based on serving size (Coenzyme Q10 | Linus Pauling Institute | Oregon State University, 2014):

  • beef, fried
  • herring, marinated
  • chicken, fried
  • rainbow trout
  • peanuts
  • sesame seeds
  • broccoli
  • cauliflower

Comprehensive food list:
Table 2. Some Common Food Sources of CoQ10
https://lpi.oregonstate.edu/mic/dietary-factors/coenzyme-Q10

CoQ10 supplementation

  • Amounts of CoQ10 used in practice and research range from 10 to 3,000 mg per day (Coenzyme Q10, 2014).
  • Typical dosing is between 30 and 120 mg a day (Gaby, 2017).

SAFETY, SIDE EFFECTS

  • There is strong evidence of safety in doses of up to 1,200 mg per day of CoQ10, and no significant side effects have been reported with doses of up to 3,000 mg per day over a period of eight months (Coenzyme Q10, 2014).
  • Mild gastrointestinal symptoms may occur in doses greater than 200 mg per day, but can be mitigated by dividing the amount taken into two or three doses throughout the day (Coenzyme Q10, 2014).

CoQ10 AND MEDICATIONS

  • CoQ10 may (Coenzyme Q10, n.d.):
    • decrease the blood thinning effect of warfarin
    • interact with prescription insulin
    • be incompatible with certain cancer treatments

Abu-Amero, K. K., Kondkar, A. A., & Chalam, K. V. (2016). Resveratrol and Ophthalmic Diseases. Nutrients, 8(4), 200. https://doi.org/10.3390/nu8040200

Ahmad, R. S., Hussain, M. B., Sultan, M. T., Arshad, M. S., Waheed, M., Shariati, M. A., Plygun, S., & Hashempur, M. H. (2020). Biochemistry, Safety, Pharmacological Activities, and Clinical Applications of Turmeric: A Mechanistic Review. Evidence-Based Complementary and Alternative Medicine : eCAM, 2020, 7656919. https://doi.org/10.1155/2020/7656919

Akhtar, A., & Sah, S. P. (2023). Chromium and Alzheimer’s disease. In Vitamins and Minerals in Neurological Disorders(pp. 87–104). Elsevier. https://doi.org/10.1016/B978-0-323-89835-5.00036-3

Alexander, J., Tinkov, A., Strand, T. A., Alehagen, U., Skalny, A., & Aaseth, J. (2020). Early Nutritional Interventions with Zinc, Selenium and Vitamin D for Raising Anti-Viral Resistance Against Progressive COVID-19. Nutrients, _12(8), Article 8. https://doi.org/10.3390/nu12082358

Anderson, T. J., Boden, W. E., Desvigne-Nickens, P., Fleg, J. L., Kashyap, M. L., McBride, R., & Probstfield, J. L. (2014). Safety Profile of Extended-Release Niacin in the AIM-HIGH Trial. New England Journal of Medicine, _371(3), 288–290. https://doi.org/10.1056/NEJMc1311039

Augustin, K., Khabbush, A., Williams, S., Eaton, S., Orford, M., Cross, J. H., Heales, S. J. R., Walker, M. C., & Williams, R. S. B. (2018). Mechanisms of action for the medium-chain triglyceride ketogenic diet in neurological and metabolic disorders. The Lancet. Neurology, 17(1), 84–93. https://doi.org/10.1016/S1474-4422(17)30408-8

Authority (EFSA), E. F. S. (2009). Labelling reference intake values for n-3 and n-6 polyunsaturated fatty acids. EFSA Journal, _7(7), 1176. https://doi.org/10.2903/j.efsa.2009.1176

Ayoub, N. M., Khalil, R. W., & Kaddoumi, A. (2023). Chapter 2—α-Tocopherol for Alzheimer’s disease. In C. R. Martin, V. B. Patel, & V. R. Preedy (Eds.), Vitamins and Minerals in Neurological Disorders (pp. 13–28). Academic Press. https://doi.org/10.1016/B978-0-323-89835-5.00015-6

Bagheri, S., Haddadi, R., Saki, S., Kourosh-Arami, M., Rashno, M., Mojaver, A., & Komaki, A. (2023). Neuroprotective effects of coenzyme Q10 on neurological diseases: A review article. Frontiers in Neuroscience, 17. https://doi.org/10.3389/fnins.2023.1188839

Banasiewicz, T., Domagalska, D., Borycka-Kiciak, K., & Rydzewska, G. (2020). Determination of butyric acid dosage based on clinical and experimental studies – a literature review. Przegla̜d Gastroenterologiczny, 15(2), 119–125. https://doi.org/10.5114/pg.2020.95556

Ben Zaken, S., Radomysky, Z., & Koren, G. (2020). Association Between Serum Magnesium Levels and Alzheimer’s Disease or Mixed Dementia Patients: A Population-Based Retrospective Controlled Study. Journal of Alzheimer’s Disease Reports, _4(1), 399–404. https://doi.org/10.3233/ADR-200220

Berger, M. M., Reymond, M. J., Shenkin, A., Rey, F., Wardle, C., Cayeux, C., Schindler, C., & Chioléro, R. L. (2001). Influence of selenium supplements on the post-traumatic alterations of the thyroid axis: A placebo-controlled trial. Intensive Care Medicine, _27(1), 91–100. https://doi.org/10.1007/s001340000757

Bermano, G., Méplan, C., Mercer, D. K., & Hesketh, J. E. (2021). Selenium and viral infection: Are there lessons for COVID-19? British Journal of Nutrition, _125(6), 618–627. https://doi.org/10.1017/S0007114520003128

Bhratee, A., Kumar, M., Alam, M. R., Anand, P., & Singh, S. (2023). Understanding Alzheimer’s Disease by Targeting Gut Microbiota and Role of Heavy Metals: Insight from Novel Therapeutical Approach. Current Pharmacology Reports, _9(4), 177–197. https://doi.org/10.1007/s40495-023-00325-z

Bigio, B., Azam, S., Mathé, A. A., & Nasca, C. (2024). The neuropsychopharmacology of acetyl-L-carnitine (LAC): Basic, translational and therapeutic implications. Discover Mental Health, 4(1), 2. https://doi.org/10.1007/s44192-023-00056-z

Boccardi, V., Baroni, M., Mangialasche, F., & Mecocci, P. (2016). Vitamin E family: Role in the pathogenesis and treatment of Alzheimer’s disease. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, _2(3), 182–191. https://doi.org/10.1016/j.trci.2016.08.002

Brown, B. I. (2017). Reversal of Alzheimer’s Disease and Optimization of Brain Health with Orthomolecular Medicine. Journal of Orthomolecular Medicine, _32(5). https://isom.ca/article/reversal-alzheimers-disease-optimization-brain-health-orthomolecular-medicine/

Brown, K., Theofanous, D., Britton, R. G., Aburido, G., Pepper, C., Sri Undru, S., & Howells, L. (2024). Resveratrol for the Management of Human Health: How Far Have We Come? A Systematic Review of Resveratrol Clinical Trials to Highlight Gaps and Opportunities. International Journal of Molecular Sciences, 25(2), 747. https://doi.org/10.3390/ijms25020747

Browne, D., McGuinness, B., Woodside, J. V., & McKay, G. J. (2019). Vitamin E and Alzheimer’s disease: What do we know so far? Clinical Interventions in Aging, 1303–1318. https://doi.org/10.2147/CIA.S186760

Butyric Acid: Its Proven and Potential Benefits. (2019, October 25). Healthline. https://www.healthline.com/health/butyric-acid

Caban, M., Pikus, E., Czarnecka-Chrebelska, K., Oszajca, K., Witusik-Perkowska, M., Dudek, J., Szemraj, J., Brzeziańska-Lasota, E., & Talar-Wojnarowska, R. (2026). Use of Sodium Butyrate and Its Microencapsulated Forms in Intestinal Diseases—Current Clinical Approach. Digestive Diseases and Sciences, 71(5), 1626–1639. https://doi.org/10.1007/s10620-025-09536-4

Castro, C. B., Dias, C. B., Hillebrandt, H., Sohrabi, H. R., Chatterjee, P., Shah, T. M., Fuller, S. J., Garg, M. L., & Martins, R. N. (2023). Medium-chain fatty acids for the prevention or treatment of Alzheimer’s disease: A systematic review and meta-analysis. Nutrition Reviews, _81(9), 1144–1162. https://doi.org/10.1093/nutrit/nuac104

Cekic, M., Sayeed, I., & Stein, D. G. (2009). Combination treatment with progesterone and vitamin D hormone may be more effective than monotherapy for nervous system injury and disease. Frontiers in Neuroendocrinology, _30(2), 158–172. https://doi.org/10.1016/j.yfrne.2009.04.002

Chakraborty, P., Gamage, H. K. A. H., & Laird, A. S. (2024). Butyrate as a potential therapeutic agent for neurodegenerative disorders. Neurochemistry International, 176, 105745. https://doi.org/10.1016/j.neuint.2024.105745

Chen, H., Meng, L., & Shen, L. (2022). Multiple roles of short-chain fatty acids in Alzheimer disease. Nutrition, 93, 111499. https://doi.org/10.1016/j.nut.2021.111499

Choline Fact Sheet for Health Professionals. (n.d.). Office of Dietary Supplements. Retrieved January 5, 2022, from https://ods.od.nih.gov/factsheets/Choline-HealthProfessional/

Choline. (2014, April 28). Linus Pauling Institute. https://lpi.oregonstate.edu/mic/other-nutrients/choline

Chromium | Linus Pauling Institute | Oregon State University. (2014, April 22). https://lpi.oregonstate.edu/mic/minerals/chromium

Chu, C.-Q., Yu, L., Qi, G., Mi, Y.-S., Wu, W.-Q., Lee, Y., Zhai, Q.-X., Tian, F.-W., & Chen, W. (2022). Can dietary patterns prevent cognitive impairment and reduce Alzheimer’s disease risk: Exploring the underlying mechanisms of effects. Neuroscience & Biobehavioral Reviews, _135(Complete). https://doi.org/10.1016/j.neubiorev.2022.104556

Dave, N., Judd, J. M., Decker, A., Winslow, W., Sarette, P., Villarreal Espinosa, O., Tallino, S., Bartholomew, S. K., Bilal, A., Sandler, J., McDonough, I., Winstone, J. K., Blackwood, E. A., Glembotski, C., Karr, T., & Velazquez, R. (2023). Dietary choline intake is necessary to prevent systems-wide organ pathology and reduce Alzheimer’s disease hallmarks. Aging Cell, _22(2), e13775. https://doi.org/10.1111/acel.13775

Dey, M., & Singh, R. K. (2022). Neurotoxic effects of aluminium exposure as a potential risk factor for Alzheimer’s disease. Pharmacological Reports, _74(3), 439–450. https://doi.org/10.1007/s43440-022-00353-4

Dhapola, R., Sharma, P., Kumari, S., Bhatti, J. S., & HariKrishnaReddy, D. (2023). Environmental Toxins and Alzheimer’s Disease: A Comprehensive Analysis of Pathogenic Mechanisms and Therapeutic Modulation. Molecular Neurobiology. https://doi.org/10.1007/s12035-023-03805-x

Dietary Reference Intakes for Calcium and Vitamin D. (2011). https://www.nationalacademies.org/projects/FNBX-H-08-08-A/publication/13050

Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. (n.d.). Retrieved July 13, 2026, from https://www.nationalacademies.org/projects/HMD-FNB-18-P-119/publication/10490

Drutel, A., Archambeaud, F., & Caron, P. (2013). Selenium and the thyroid gland: More good news for clinicians. Clinical Endocrinology, _78(2), 155–164. https://doi.org/10.1111/cen.12066

Elias, A., Padinjakara, N., & Lautenschlager, N. T. (2023). Effects of intermittent fasting on cognitive health and Alzheimer’s disease. Nutrition Reviews, _81(9), 1225–1233. https://doi.org/10.1093/nutrit/nuad021

Ellouze, I., Sheffler, J., Nagpal, R., & Arjmandi, B. (2023). Dietary Patterns and Alzheimer’s Disease: An Updated Review Linking Nutrition to Neuroscience. Nutrients, _15(14), Article 14. https://doi.org/10.3390/nu15143204

El-Mezayen, N. S., Abd el Moneim, Rehab. A., & El-Rewini, S. H. (2022). Vitamin B12 as a cholinergic system modulator and blood brain barrier integrity restorer in Alzheimer’s disease. European Journal of Pharmaceutical Sciences, 174, 106201. https://doi.org/10.1016/j.ejps.2022.106201

Erol, S. A., Polat, N., Akdas, S., Aribal Ayral, P., Anuk, A. T., Ozden Tokalioglu, E., Goncu Ayhan, Ş., Kesikli, B., Ceylan, M. N., Tanacan, A., Moraloglu Tekin, Ö., Yazihan, N., & Sahin, D. (2021). Maternal selenium status plays a crucial role on clinical outcomes of pregnant women with COVID-19 infection. Journal of Medical Virology, _93(9), 5438–5445. https://doi.org/10.1002/jmv.27064

Escobedo-Monge, M. F., Barrado, E., Parodi-Román, J., Escobedo-Monge, M. A., Torres-Hinojal, M. C., & Marugán-Miguelsanz, J. M. (2021). Copper and Copper/Zn Ratio in a Series of Children with Chronic Diseases: A Cross-Sectional Study. Nutrients, _13(10), 3578. https://doi.org/10.3390/nu13103578

Essential Fatty Acids. (2014, April 28). Linus Pauling Institute. https://lpi.oregonstate.edu/mic/other-nutrients/essential-fatty-acids

Fatima, G., Dzupina, A., B Alhmadi, H., Magomedova, A., Siddiqui, Z., Mehdi, A., & Hadi, N. (2024). Magnesium Matters: A Comprehensive Review of Its Vital Role in Health and Diseases. Cureus, _16(10), e71392. https://doi.org/10.7759/cureus.71392

Fernando, B., Brennan, C., S., & Martins, R., N. (2019). The Products of Fermentation and Their Effects on Metabolism, Alzheimer’s Disease, and Other Neurodegenerative Diseases: Role of Short-Chain Fatty Acids (SCFA). In Neurodegeneration and Alzheimer’s Disease (pp. 311–333). John Wiley & Sons, Ltd. https://doi.org/10.1002/9781119356752.ch11

Ferracioli-Oda, E., Qawasmi, A., & Bloch, M. H. (2013). Meta-analysis: Melatonin for the treatment of primary sleep disorders. PloS One, _8(5), e63773. https://doi.org/10.1371/journal.pone.0063773

Fessel, J. (2021). Supplemental thiamine as a practical, potential way to prevent Alzheimer’s disease from commencing. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, _7(1), e12199. https://doi.org/10.1002/trc2.12199

Fišar, Z., & Hroudová, J. (2024). CoQ10 and Mitochondrial Dysfunction in Alzheimer’s Disease. Antioxidants, _13(2), 191. https://doi.org/10.3390/antiox13020191

Fogacci, F., Rizzo, M., Krogager, C., Kennedy, C., Georges, C. M. G., Knežević, T., Liberopoulos, E., Vallée, A., Pérez-Martínez, P., Wenstedt, E. F. E., Šatrauskienė, A., Vrablík, M., & Cicero, A. F. G. (2020). Safety Evaluation of α-Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies. Antioxidants, 9(10), 1011. https://doi.org/10.3390/antiox9101011

Folate. (2014, April 22). Linus Pauling Institute. https://lpi.oregonstate.edu/mic/vitamins/folate

Freeman, W. H. (1973). Vitamin C: New biochemical and functional insights. In Orthomolecular psychiatry.

Fuso, A., Cavallaro, R. A., Zampelli, A., D’Anselmi, F., Piscopo, P., Confaloni, A., & Scarpa, S. (2007). γ-Secretase is Differentially Modulated by Alterations of Homocysteine Cycle in Neuroblastoma and Glioblastoma Cells. Journal of Alzheimer’s Disease, _11(3), 275–290. https://doi.org/10.3233/JAD-2007-11303

Gaby, A. R. (2011). Nutritional Medicine (VitalBook file).

Galley, H. F., Lowes, D. A., Allen, L., Cameron, G., Aucott, L. S., & Webster, N. R. (2014). Melatonin as a potential therapy for sepsis: A phase I dose escalation study and an ex vivo whole blood model under conditions of sepsis. Journal of Pineal Research, _56(4), 427–438. https://doi.org/10.1111/jpi.12134

Gammoh, N. Z., & Rink, L. (2017). Zinc in Infection and Inflammation. Nutrients, _9(6), Article 6. https://doi.org/10.3390/nu9060624

Gibson, G. E., Hirsch, J. A., Fonzetti, P., Jordan, B. D., Cirio, R. T., & Elder, J. (2016). Vitamin B1 (thiamine) and dementia. Annals of the New York Academy of Sciences, _1367(1), 21–30. https://doi.org/10.1111/nyas.13031

Gibson, G. E., Luchsinger, J. A., Cirio, R., Chen, H., Franchino-Elder, J., Hirsch, J. A., Bettendorff, L., Chen, Z., Flowers, S. A., Gerber, L. M., Grandville, T., Schupf, N., Xu, H., Stern, Y., Habeck, C., Jordan, B., & Fonzetti, P. (2020). Benfotiamine and Cognitive Decline in Alzheimer’s Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial. Journal of Alzheimer’s Disease: JAD, _78(3), 989–1010. https://doi.org/10.3233/JAD-200896

Gireadă, B., Nita, I. B., Dobrin, I., Chirita, V., Chirita, R., & Dobrin, R. (2022). Treatment strategies in Alzheimer’s disease: A mini-review of literature with focus on selenium supplementation. Bulletin of Integrative Psychiatry, _95(4), 45–52. https://doi.org/10.36219/BPI.2022.4.06

Gregory, J. F., DeRatt, B. N., Rios-Avila, L., Ralat, M., & Stacpoole, P. W. (2016). Vitamin B6 Nutritional Status and Cellular Availability of Pyridoxal 5’-Phosphate Govern the Function of the Transsulfuration Pathway’s Canonical Reactions and Hydrogen Sulfide Production via Side Reactions. Biochimie, 126, 21–26. https://doi.org/10.1016/j.biochi.2015.12.020

Gröber, U., & Holick, M. F. (2022). The coronavirus disease (COVID-19) – A supportive approach      with selected micronutrients. International Journal for Vitamin and Nutrition Research, _92(1), 13–34. https://doi.org/10.1024/0300-9831/a000693

Gueimonde, M., Sánchez, B., G. de los Reyes-Gavilán, C., & Margolles, A. (2013). Antibiotic resistance in probiotic bacteria. Frontiers in Microbiology, 4, 202. https://doi.org/10.3389/fmicb.2013.00202

Hamid, M., Mansoor, S., Amber, S., & Zahid, S. (2022). A quantitative meta-analysis of vitamin C in the pathophysiology of Alzheimer’s disease. Frontiers in Aging Neuroscience, 14. https://doi.org/10.3389/fnagi.2022.970263

Hegde, M., Girisa, S., BharathwajChetty, B., Vishwa, R., & Kunnumakkara, A. B. (2023). Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far? ACS Omega, 8(12), 10713–10746. https://doi.org/10.1021/acsomega.2c07326

Heidt, C., Oertling, H., Abramowicz, M., Otsubo, Y., Tokunaga, S., & Tsujino, S. (2026). Medium-Chain Triglycerides: Scientific and Regulatory Perspectives from Germany and Japan with a US Context—A Concise Review. Nutrients, 18(7), 1027. https://doi.org/10.3390/nu18071027

Heo, J.-H., Hyon-Lee, & Lee, K.-M. (2013). The Possible Role of Antioxidant Vitamin C in Alzheimer’s Disease Treatment and Prevention. American Journal of Alzheimer’s Disease & Other Dementias®, _28(2), 120–125. https://doi.org/10.1177/1533317512473193

Hewlings, S. J., & Kalman, D. S. (2017). Curcumin: A Review of Its’ Effects on Human Health. Foods, 6(10), 92. https://doi.org/10.3390/foods6100092

Hoffer, A. (1971). Vitamin B3 Dependent Child. Schizophrenia.

Hoffer, A. (1999). Dr. Hoffer’s ABC of Natural Nutrition for Children: With Learning Disabilities, Behavioral Disorders, and Mental State Dysfunctions. CCNM Press.

Hoffer, A.(1995). Vitamin B-3: Niacin and its amide. Townsend Letter for Doctors & Patients 147:30-39.

Hoffer, A., Saul, A., & Foster, H. D. (1995). Niacin: The Real Story.

Hosseini Dastgerdi, A., Ghanbari Rad, M., & Soltani, N. (2022). The Therapeutic Effects of Magnesium in Insulin Secretion and Insulin Resistance. Advanced Biomedical Research, 11, 54. https://doi.org/10.4103/abr.abr_366_21

Houston, M. C., & Harper, K. J. (2008). Potassium, Magnesium, and Calcium: Their Role in Both the Cause and Treatment of Hypertension. The Journal of Clinical Hypertension, _10(7), 3–11. https://doi.org/10.1111/j.1751-7176.2008.08575.x

Huang, Y., Deng, Y., Zhang, P., Lin, J., Guo, D., Yang, L., Liu, D., Xu, B., Huang, C., & Zhang, H. (2022). Associations of fish oil supplementation with incident dementia: Evidence from the UK Biobank cohort study. Frontiers in Neuroscience, 16, 910977. https://doi.org/10.3389/fnins.2022.910977

Hussain, Y., Abdullah, Khan, F., Alsharif, K. F., Alzahrani, K. J., Saso, L., & Khan, H. (2022). Regulatory Effects of Curcumin on Platelets: An Update and Future Directions. Biomedicines, 10(12), 3180. https://doi.org/10.3390/biomedicines10123180

Iddir, M., Brito, A., Dingeo, G., Fernandez Del Campo, S. S., Samouda, H., La Frano, M. R., & Bohn, T. (2020). Strengthening the Immune System and Reducing Inflammation and Oxidative Stress through Diet and Nutrition: Considerations during the COVID-19 Crisis. Nutrients, _12(6). https://doi.org/10.3390/nu12061562

Institute of Medicine (Ed.). (2005). Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids. National Academy Press.

Institute of Medicine. (2006). Dietary reference intakes: The essential guide to nutrient requirements. National Academies Press. https://doi.org/10.17226/11537

Jadhav, H. B., & Annapure, U. S. (2023). Triglycerides of medium-chain fatty acids: A concise review. Journal of Food Science and Technology, 60(8), 2143–2152. https://doi.org/10.1007/s13197-022-05499-w

Katkowska, M., Garbacz, K., & Kusiak, A. (2021). Probiotics: Should All Patients Take Them? Microorganisms, 9(12), 2620. https://doi.org/10.3390/microorganisms9122620

Kelesidis, T., & Pothoulakis, C. (2012). Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therapeutic Advances in Gastroenterology, 5(2), 111–125. https://doi.org/10.1177/1756283X11428502

Kennedy, D. O. (2016). B Vitamins and the Brain: Mechanisms, Dose and Efficacy—A Review. Nutrients, _8(2), 68. https://doi.org/10.3390/nu8020068

Khatiwada, S., & Subedi, A. (2021). A Mechanistic Link Between Selenium and Coronavirus Disease 2019 (COVID-19). Current Nutrition Reports, _10(2), 125–136. https://doi.org/10.1007/s13668-021-00354-4

Kouba, B. R., Camargo, A., & Rodrigues, A. L. S. (2023). Neuroinflammation in Alzheimer’s disease: Potential beneficial effects of vitamin D. Metabolic Brain Disease, _38(3), 819–829. https://doi.org/10.1007/s11011-023-01188-5

Kunnumakkara, A. B., Hegde, M., Parama, D., Girisa, S., Kumar, A., Daimary, U. D., Garodia, P., Yenisetti, S. C., Oommen, O. V., & Aggarwal, B. B. (2023). Role of Turmeric and Curcumin in Prevention and Treatment of Chronic Diseases: Lessons Learned from Clinical Trials. ACS Pharmacology & Translational Science, 6(4), 447–518. https://doi.org/10.1021/acsptsci.2c00012

Lam, V., Hackett, M., & Takechi, R. (2016). Antioxidants and Dementia Risk: Consideration through a Cerebrovascular Perspective. Nutrients, _8(12), Article 12. https://doi.org/10.3390/nu8120828

Lasoń, W., Jantas, D., Leśkiewicz, M., Regulska, M., & Basta-Kaim, A. (2023). The Vitamin D Receptor as a Potential Target for the Treatment of Age-Related Neurodegenerative Diseases Such as Alzheimer’s and Parkinson’s Diseases: A Narrative Review. Cells, _12(4), 660. https://doi.org/10.3390/cells12040660

Lau, Y. C. C., Ding, J. A., Simental, A., Mirzoyan, H., Lee, W., Diamante, G., Cely, I., Tran, M., Morselli, M., Dang, J., Kaczor-Urbanowicz, K. E., Sayre, J., Stiles, L., Yang, X., Pellegrini, M., & Fiala, M. (2020). Omega-3 fatty acids increase OXPHOS energy for immune therapy of Alzheimer disease patients. The FASEB Journal, _34(8), 9982–9994. https://doi.org/10.1096/fj.202000669RR

Lauer, A. A., Grimm, H. S., Apel, B., Golobrodska, N., Kruse, L., Ratanski, E., Schulten, N., Schwarze, L., Slawik, T., Sperlich, S., Vohla, A., & Grimm, M. O. W. (2022). Mechanistic Link between Vitamin B12 and Alzheimer’s Disease. Biomolecules, _12(1), Article 1. https://doi.org/10.3390/biom12010129

Lilamand, M., Mouton-Liger, F., & Paquet, C. (2021). Ketogenic diet therapy in Alzheimer’s disease: An updated review. Current Opinion in Clinical Nutrition & Metabolic Care, _24(4), 372–378. https://doi.org/10.1097/MCO.0000000000000759

Lloret, A., Esteve, D., Monllor, P., Cervera-Ferri, A., & Lloret, A. (2019). The Effectiveness of Vitamin E Treatment in Alzheimer’s Disease. International Journal of Molecular Sciences, _20(4), Article 4. https://doi.org/10.3390/ijms20040879

Maccioni, R. B., Calfío, C., González, A., & Lüttges, V. (2022). Novel Nutraceutical Compounds in Alzheimer Prevention. Biomolecules, _12(2), Article 2. https://doi.org/10.3390/biom12020249

Magnesium | Linus Pauling Institute | Oregon State University. (2014, April 23). https://lpi.oregonstate.edu/mic/minerals/magnesium

Malhotra, S., Sawhney, G., & Pandhi, P. (2004). The Therapeutic Potential of Melatonin: A Review of the Science. Medscape General Medicine, _6(2), 46. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1395802/

Marco, M. L., Heeney, D., Binda, S., Cifelli, C. J., Cotter, P. D., Foligné, B., Gänzle, M., Kort, R., Pasin, G., Pihlanto, A., Smid, E. J., & Hutkins, R. (2017). Health benefits of fermented foods: Microbiota and beyond. Current Opinion in Biotechnology, Food Biotechnology • Plant Biotechnology, 44, 94–102. https://doi.org/10.1016/j.copbio.2016.11.010

Marco, M. L., Sanders, M. E., Gänzle, M., Arrieta, M. C., Cotter, P. D., De Vuyst, L., Hill, C., Holzapfel, W., Lebeer, S., Merenstein, D., Reid, G., Wolfe, B. E., & Hutkins, R. (2021). The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on fermented foods. Nature Reviews Gastroenterology & Hepatology, 18(3), 196–208. https://doi.org/10.1038/s41575-020-00390-5

Marino, A. L., Wilcox, J. M., & Harrison, F. E. (2023). Vitamin C is protective against a microglial inflammatory phenotype following LPS exposure. Alzheimer’s & Dementia, _19(S13), e074154. https://doi.org/10.1002/alz.074154

Meng, X., Li, Y., Li, S., Zhou, Y., Gan, R.-Y., Xu, D.-P., & Li, H.-B. (2017). Dietary Sources and Bioactivities of Melatonin. Nutrients, _9(4), Article 4. https://doi.org/10.3390/nu9040367

Merenstein, D., Pot, B., Leyer, G., Ouwehand, A. C., Preidis, G. A., Elkins, C. A., Hill, C., Lewis, Z. T., Shane, A. L., Zmora, N., Petrova, M. I., Collado, M. C., Morelli, L., Montoya, G. A., Szajewska, H., Tancredi, D. J., & Sanders, M. E. (n.d.). Emerging issues in probiotic safety: 2023 perspectives. Gut Microbes, 15(1), 2185034. https://doi.org/10.1080/19490976.2023.2185034

Methylcobalamin. (1998). Alternative Medicine Review: A Journal of Clinical Therapeutic, _3(6), 461–463.

Miodownik, C., Cohen, H., Kotler, M., & Lerner, V. (2003). [Vitamin B6 add-on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders]. Harefuah, _142(8–9), 592–596, 647.

Morris, M., Evans, D., Bienias, J., Scherr, P., Tangney, C., Hebert, L., Bennett, D., Wilson, R., & Aggarwal, N. (2004). Dietary niacin and the risk of incident Alzheimer’s disease and of cognitive decline. Journal of Neurology, Neurosurgery, and Psychiatry, _75(8), 1093–1099. https://doi.org/10.1136/jnnp.2003.025858

Moutinho, M., Tsai, A. P., Puntambekar, S. S., Patel, J., Lin, P. B., Jadhav, V., Williams, R. Y., Shekhar, A., & Landreth, G. E. (2020). Therapeutic potential of niacin in Alzheimer’s disease. Alzheimer’s & Dementia, _16(S9), e040679. https://doi.org/10.1002/alz.040679

Mukhopadhya, I., & Louis, P. (2025). Gut microbiota-derived short-chain fatty acids and their role in human health and disease. Nature Reviews Microbiology, 23(10), 635–651. https://doi.org/10.1038/s41579-025-01183-w

Niacin | Linus Pauling Institute | Oregon State University. (2014, April 22). https://lpi.oregonstate.edu/mic/vitamins/niacin

Norwitz, N. G., Saif, N., Ariza, I. E., & Isaacson, R. S. (2021). Precision Nutrition for Alzheimer’s Prevention in ApoE4 Carriers. Nutrients, _13(4), Article 4. https://doi.org/10.3390/nu13041362

Office of Dietary Supplements—Carnitine. (n.d.). Retrieved July 20, 2026, from https://ods.od.nih.gov/factsheets/Carnitine-HealthProfessional/?crsi=4077191131&utm_source=chatgpt.com

Office of Dietary Supplements—Selenium. (n.d.). Retrieved September 3, 2022, from https://ods.od.nih.gov/factsheets/Selenium-HealthProfessional/

Office of Dietary Supplements—Vitamin B6. (n.d.). Retrieved October 28, 2020, from https://ods.od.nih.gov/factsheets/VitaminB6-HealthProfessional/

Office of Dietary Supplements—Vitamin C. (n.d.). Retrieved December 22, 2021, from https://ods.od.nih.gov/factsheets/VitaminC-HealthProfessional/

Office of Dietary Supplements—Vitamin D. (n.d.). Retrieved July 13, 2026, from https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

Office of Dietary Supplements—Vitamin E. (n.d.). Retrieved September 3, 2022, from https://ods.od.nih.gov/factsheets/VitaminE-HealthProfessional/

Office of Dietary Supplements—Zinc. (2014). https://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/

Pan, X., Gong, N., Zhao, J., Yu, Z., Gu, F., Chen, J., Sun, X., Zhao, L., Yu, M., Xu, Z., Dong, W., Qin, Y., Fei, G., Zhong, C., & Xu, T.-L. (2010). Powerful beneficial effects of benfotiamine on cognitive impairment and β-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Brain, _133(5), 1342–1351. https://doi.org/10.1093/brain/awq069

Paules, E. M., Petry, H. G., Sprinkles, J. K., & Trujillo-Gonzalez, I. (2025). Future Directions in Choline: From Neurodevelopment to Cardiometabolic Health. Nutrients, _17(22), 3618. https://doi.org/10.3390/nu17223618

Pauling, L., Robinson, A., Oxley, S., Bergeson, M., Harris, A., Cary, P., … Keaveny, I. (1973). Vitamin C: New biochemical and functional insights. In D. Hawkins & L. Pauling (Eds.), Orthomolecular psychiatry. W. H. Freeman.

Pennisi, M., Lanza, G., Cantone, M., D’Amico, E., Fisicaro, F., Puglisi, V., Vinciguerra, L., Bella, R., Vicari, E., & Malaguarnera, G. (2020). Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update. Nutrients, 12(5), 1389. https://doi.org/10.3390/nu12051389

Pereira, M. E., Souza, J. V., Galiciolli, M. E. A., Sare, F., Vieira, G. S., Kruk, I. L., & Oliveira, C. S. (2022). Effects of Selenium Supplementation in Patients with Mild Cognitive Impairment or Alzheimer’s Disease: A Systematic Review and Meta-Analysis. Nutrients, _14(15), Article 15. https://doi.org/10.3390/nu14153205

Peres, E., Francisco, S., Medroa, T., Joaquim, J., & Baltazar, A. (2022). Is There an Important Role Played by Thiamine (Vit B1) in Alzheimer’s Disease? Drug Safety: An International Journal of Medical Toxicology and Drug Experience, _45(10), 1296. https://www.proquest.com/docview/2718388626/abstract/419130ABF76E4858PQ/1

Pi, T., Liu, B., & Shi, J. (2020). Abnormal Homocysteine Metabolism: An Insight of Alzheimer’s Disease from DNA Methylation. Behavioural Neurology, 2020, e8438602. https://doi.org/10.1155/2020/8438602

Plevin, D., & Galletly, C. (2020). The neuropsychiatric effects of vitamin C deficiency: A systematic review. BMC Psychiatry, _20(1), 315. https://doi.org/10.1186/s12888-020-02730-w

Prousky, J. (2015). Anxiety: Orthomolecular diagnosis and treatment (Kindle). CCNM Press.

Prousky, J. E. (2010). Understanding the Serum Vitamin B12 Level and its Implications for Treating Neuropsychiatric Conditions: An Orthomolecular Perspective. _25(2).

Rao, R. V., Subramaniam, K. G., Gregory, J., Bredesen, A. L., Coward, C., Okada, S., Kelly, L., & Bredesen, D. E. (2023). Rationale for a Multi-Factorial Approach for the Reversal of Cognitive Decline in Alzheimer’s Disease and MCI: A Review. International Journal of Molecular Sciences, _24(2), Article 2. https://doi.org/10.3390/ijms24021659

Rivers-Auty, J., Tapia, V. S., White, C. S., Daniels, M. J. D., Drinkall, S., Kennedy, P. T., Spence, H. G., Yu, S., Green, J. P., Hoyle, C., Cook, J., Bradley, A., Mather, A. E., Peters, R., Tzeng, T.-C., Gordon, M. J., Beattie, J. H., Brough, D., & Lawrence, C. B. (2021). Zinc Status Alters Alzheimer’s Disease Progression through NLRP3-Dependent Inflammation. The Journal of Neuroscience, _41(13), 3025–3038. https://doi.org/10.1523/JNEUROSCI.1980-20.2020

Romanenko, M., Kholin, V., Koliada, A., & Vaiserman, A. (2021). Nutrition, Gut Microbiota, and Alzheimer’s Disease. Frontiers in Psychiatry, 12. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2021.712673

Ryan, J. J., & Patno, N. M. (2021). Short-Term Tolerability, Safety, and Gut Microbial Composition Responses to a Multi-Strain Probiotic Supplement: An Open-Label Study in Healthy Adults. Integrative Medicine: A Clinician’s Journal, 20(1), 24–34. https://pmc.ncbi.nlm.nih.gov/articles/PMC8352413/

Salehi, B., Berkay Yılmaz, Y., Antika, G., Boyunegmez Tumer, T., Fawzi Mahomoodally, M., Lobine, D., Akram, M., Riaz, M., Capanoglu, E., Sharopov, F., Martins, N., Cho, W. C., & Sharifi-Rad, J. (2019). Insights on the Use of α-Lipoic Acid for Therapeutic Purposes. Biomolecules, 9(8), 356. https://doi.org/10.3390/biom9080356

Sanders, M. E., Merenstein, D., Merrifield, C. A., & Hutkins, R. (2018). Probiotics for human use. Nutrition Bulletin, 43(3), 212–225. https://doi.org/10.1111/nbu.12334

Sestili, P., & Fimognari, C. (2020). Paracetamol-Induced Glutathione Consumption: Is There a Link With Severe COVID-19 Illness? Frontiers in Pharmacology, 11, 579944. https://doi.org/10.3389/fphar.2020.579944

Shaito, A., Posadino, A. M., Younes, N., Hasan, H., Halabi, S., Alhababi, D., Al-Mohannadi, A., Abdel-Rahman, W. M., Eid, A. H., Nasrallah, G. K., & Pintus, G. (2020). Potential Adverse Effects of Resveratrol: A Literature Review. International Journal of Molecular Sciences, 21(6), 2084. https://doi.org/10.3390/ijms21062084

Smith, A. D., Refsum, H., Bottiglieri, T., Fenech, M., Hooshmand, B., McCaddon, A., Miller, J. W., Rosenberg, I. H., & Obeid, R. (2018). Homocysteine and Dementia: An International Consensus Statement1. Journal of Alzheimer’s Disease, _62(2), 561–570. https://doi.org/10.3233/JAD-171042

Sontag, J.-M., & Sontag, E. (2014). Protein phosphatase 2A dysfunction in Alzheimer’s disease. Frontiers in Molecular Neuroscience, 7. https://doi.org/10.3389/fnmol.2014.00016

Suboticanec, K., Folnegović-Smalc, V., Korbar, M., Mestrović, B., & Buzina, R. (1990). Vitamin C status in chronic schizophrenia. Biological Psychiatry, _28(11), 959–966. https://doi.org/10.1016/0006-3223(90)90061-6

Tao, M.-H., Liu, J., & Cervantes, D. (2022). Association between magnesium intake and cognition in US older adults: National Health and Nutrition Examination Survey (NHANES) 2011 to 2014. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, _8(1), e12250. https://doi.org/10.1002/trc2.12250

Thiamin. (2014, April 22). Linus Pauling Institute.
(https://lpi.oregonstate.edu/mic/vitamins/thiamin

Thiel, A., Hermanns, C., Lauer, A. A., Jö, Reichrath, R., Erhardt, T., Hartmann, T., Grimm, M. O. W., & Grimm, H. S. (2023). Vitamin D and Its Analogues: From Differences in Molecular Mechanisms to Potential Benefits of Adapted Use in the Treatment of Alzheimer’s Disease. Nutrients, _15(7), NA-NA. https://doi.org/10.3390/nu15071684

Vinuesa, A., Pomilio, C., Gregosa, A., Bentivegna, M., Presa, J., Bellotto, M., Saravia, F., & Beauquis, J. (2021). Inflammation and Insulin Resistance as Risk Factors and Potential Therapeutic Targets for Alzheimer’s Disease. Frontiers in Neuroscience, 15. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2021.653651

Vitamin B12. (2014, April 22). Linus Pauling Institute. https://lpi.oregonstate.edu/mic/vitamins/vitamin-B12

Vitamin B6. (2014, April 22). Linus Pauling Institute. https://lpi.oregonstate.edu/mic/vitamins/vitamin-B6

Vitamin C. (2014, April 22). Linus Pauling Institute. https://lpi.oregonstate.edu/mic/vitamins/vitamin-C

Vitamin D | Linus Pauling Institute | Oregon State University. (2014, April 22). https://lpi.oregonstate.edu/mic/vitamins/vitamin-D

Vogel-González, M., Talló-Parra, M., Herrera-Fernández, V., Pérez-Vilaró, G., Chillón, M., Nogués, X., Gómez-Zorrilla, S., López-Montesinos, I., Arnau-Barrés, I., & Sorli-Redó, M. L. (2021). Low zinc levels at admission associates with poor clinical outcomes in SARS-CoV-2 infection. Nutrients, _13(2), 562.

Volak, L. P., Ghirmai, S., Cashman, J. R., & Court, M. H. (2008). Curcuminoids inhibit multiple human cytochromes P450 (CYP), UDP-glucuronosyltransferase (UGT), and sulfotransferase (SULT) enzymes, while piperine is a relatively selective CYP3A4 inhibitor. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 36(8), 1594–1605. https://doi.org/10.1124/dmd.108.020552

Wang, J., Yu, Z., Peng, Y., & Xu, B. (2023). Insights into prevention mechanisms of bioactive components from healthy diets against Alzheimer’s disease. The Journal of Nutritional Biochemistry, _119(Complete). https://doi.org/10.1016/j.jnutbio.2023.109397

Werbach, M. R., & Leibsohn, G. B. M. A. (1997). Adverse effects of nutritional supplements. In Foundations of Nutritional Medicine: A Sourcebook of Clinical Research. Third Line Press.

Xie, Z., Chen, F., Li, W. A., Geng, X., Li, C., Meng, X., Feng, Y., Liu, W., & Yu, F. (2017). A review of sleep disorders and melatonin. Neurological Research, _39(6), 559–565. https://doi.org/10.1080/01616412.2017.1315864

Xu Lou, I., Ali, K., & Chen, Q. (2023). Effect of nutrition in Alzheimer’s disease: A systematic review. Frontiers in Neuroscience, 17. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2023.1147177

Xue, B., Waseem, S. M. A., Zhu, Z., Alshahrani, M. A., Nazam, N., Anjum, F., Habib, A. H., Rafeeq, M. M., Nazam, F., & Sharma, M. (2022). Brain-Derived Neurotrophic Factor: A Connecting Link Between Nutrition, Lifestyle, and Alzheimer’s Disease. Frontiers in Neuroscience, 16. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2022.925991

Zhang, X., Bao, G., Liu, D., Yang, Y., Li, X., Cai, G., Liu, Y., & Wu, Y. (2021). The Association Between Folate and Alzheimer’s Disease: A Systematic Review and Meta-Analysis. Frontiers in Neuroscience, 15. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2021.661198

Zhang, X., Tong, T., Chang, A., Ang, T. F. A., Tao, Q., Auerbach, S., Devine, S., Qiu, W. Q., Mez, J., Massaro, J., Lunetta, K. L., Au, R., & Farrer, L. A. (2023). Midlife lipid and glucose levels are associated with Alzheimer’s disease. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, _19(1), 181–193. https://doi.org/10.1002/alz.12641

Zinc | Linus Pauling Institute | Oregon State University. (2014, April 23). https://lpi.oregonstate.edu/mic/minerals/zinc

These orthomolecular interventions are intended to support the body’s natural biochemical processes by addressing nutritional deficiencies, reducing oxidative stress, supporting mitochondrial function, and promoting healthy brain function.

The Basic First Steps section highlights the foundational lifestyle and dietary strategies that form the basis of a comprehensive approach to supporting brain health.